Biotech And Pharma Industry Stocks 0


Screener
The Min must be less that the Max.
Name PRICE MARKET CAPITALIZATION PRICE TO EARNINGS RATIO DIVIDEND YIELD SYMBOL EXCHANGE PRICE PERCENT DIFFERENCE YEAR TO DATE PRICE PERCENT DIFFERENCE 5 YEAR CHART 1 YEAR CHART

AbbVie is a drug company with a strong exposure to immunology and oncology. The company's top drug, Humira, represents over half of the company's current profits. The company was spun off from Abbott in early 2013.

http://www.abbvieinvestor.com


ABBV $79.76 -1.48 (-1.82%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 119.84 Billion
EPS -1.14 P/E Ratio 21.79
Previous Earnings Fri, Nov 2, 2018
Latest Earnings Fri, Jan 25, 2019
Dividend 5.37% / $4.28
Ex-Date Fri, Apr 12, 2019
Dividend Pay Date Wed, May 15, 2019
Dividend History 26 Payments (Quarterly)

79.76 119.84 21.79 5.37 ABBV NYSE -1.82 -10.61 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ABBV&exchange=NYSE&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ABBV&exchange=NYSE&chart=1

Allergan is one of the largest specialty pharmaceutical manufacturers. It specializes in aesthetics, ophthalmology, women's health, gastrointestinal, and central nervous system products. In 2016, Allergan sold its generics and distribution segments to Teva.

http://www.allergan.com


AGN $149.30 -4.23 (-2.76%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 51.07 Billion
EPS -12.76 P/E Ratio 0.00
Previous Earnings Tue, Oct 30, 2018
Latest Earnings Tue, Jan 29, 2019
Dividend 1.98% / $2.96
Ex-Date Thu, Feb 14, 2019
Dividend Pay Date Fri, Mar 15, 2019
Dividend History 9 Payments (Quarterly)

149.30 51.07 0.00 1.98 AGN NYSE -2.76 9.88 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AGN&exchange=NYSE&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AGN&exchange=NYSE&chart=1

Alexion Pharmaceuticals specializes in developing and marketing drugs for rare, life-threatening medical conditions. Its blockbuster product, Soliris, is approved for paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and generalized myasthenia gravis. Next-generation Ultomiris was recently approved in paroxysmal nocturnal hemoglobinuria. Strensiq and Kanuma target other ultrarare metabolic diseases. Alexion's pipeline targets rare diseases with high unmet need and complement-mediated disorders.

http://www.alexion.com


ALXN $130.21 -4.00 (-2.98%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 29.72 Billion
EPS -0.20 P/E Ratio 372.03
Previous Earnings Wed, Oct 24, 2018
Latest Earnings Mon, Feb 4, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

130.21 29.72 372.03 0.00 ALXN NASDAQ -2.98 32.80 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ALXN&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ALXN&exchange=NASDAQ&chart=1

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and received approval for bone-strengthening drug Prolia/Xgeva in 2010. Amgen's acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Nexavar and Kyprolis. Recent launches include Repatha (cholesterol-lowering) and Aimovig (migraine).

http://www.amgen.com


AMGN $186.70 -5.19 (-2.70%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 117.42 Billion
EPS 3.03 P/E Ratio 14.79
Previous Earnings Tue, Oct 30, 2018
Latest Earnings Tue, Jan 29, 2019
Dividend 3.11% / $5.80
Ex-Date Thu, May 16, 2019
Dividend Pay Date Fri, Jun 7, 2019
Dividend History 32 Payments (Quarterly)

186.70 117.42 14.79 3.11 AMGN NASDAQ -2.70 -2.71 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AMGN&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AMGN&exchange=NASDAQ&chart=1

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Tysabri and Tecfidera. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis.

http://www.biogen.com


BIIB $216.71 -10.17 (-4.48%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 44.63 Billion
EPS 4.77 P/E Ratio 10.04
Previous Earnings Tue, Oct 23, 2018
Latest Earnings Tue, Jan 29, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

216.71 44.63 10.04 0.00 BIIB NASDAQ -4.48 -28.88 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=BIIB&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=BIIB&exchange=NASDAQ&chart=1

BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). BioMarin has a hemophilia A gene therapy and a treatment for achondroplasia in late-stage clinical trials.

http://www.bmrn.com


BMRN $88.05 -2.73 (-3.01%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 16.19 Billion
EPS -0.02 P/E Ratio 0.00
Previous Earnings Thu, Oct 25, 2018
Latest Earnings Thu, Feb 21, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

88.05 16.19 0.00 0.00 BMRN NASDAQ -3.01 3.64 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=BMRN&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=BMRN&exchange=NASDAQ&chart=1

Bristol-Myers Squibb Co discovers, develops, and markets drugs for various indications, such as cardiovascular, oncology, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is leading in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs.

http://www.bms.com


BMY $48.16 -0.76 (-1.55%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 79.87 Billion
EPS 0.71 P/E Ratio 15.89
Previous Earnings Thu, Oct 25, 2018
Latest Earnings Thu, Jan 24, 2019
Dividend 3.41% / $1.64
Ex-Date Thu, Apr 4, 2019
Dividend Pay Date Wed, May 1, 2019
Dividend History 134 Payments (Quarterly)

48.16 79.87 15.89 3.41 BMY NYSE -1.55 -7.42 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=BMY&exchange=NYSE&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=BMY&exchange=NYSE&chart=1

Celgene is a biopharmaceutical firm that discovers, develops, and markets therapeutics for the treatment of cancer and immunological diseases. Celgene markets Thalomid and Pomalyst to treat multiple myeloma and Revlimid, a less toxic thalidomide derivative, to treat myelodysplastic syndromes, multiple myeloma, and mantle cell lymphoma. Acquisitions have brought MDS drug Vidaza, T-cell lymphoma drug Istodax, and cancer drug Abraxane. The firm's first immunology drug, Otezla, was approved in the U.S. in 2014. Recent acquisitions of Juno and Impact bring additional drugs for Celgene's blood cancer pipeline.

http://www.celgene.com


CELG $88.15 -1.48 (-1.65%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 62.95 Billion
EPS 1.53 P/E Ratio 17.70
Previous Earnings Thu, Oct 25, 2018
Latest Earnings Thu, Jan 31, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

88.15 62.95 17.70 0.00 CELG NASDAQ -1.65 32.28 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CELG&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CELG&exchange=NASDAQ&chart=1

After a string of acquisitions and divestitures, Endo is a specialty pharmaceutical company with a considerable presence in pain management. The acquisitions of Auxilium and Par increased the company's presence in urology and generics, respectively.

http://www.endo.com


ENDP $8.33 -0.43 (-4.91%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 1.91 Billion
EPS -1.31 P/E Ratio 0.00
Previous Earnings Thu, Nov 8, 2018
Latest Earnings Thu, Feb 28, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

8.33 1.91 0.00 0.00 ENDP NASDAQ -4.91 8.04 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ENDP&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ENDP&exchange=NASDAQ&chart=1

Gilead Sciences Inc develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite acquisition boosted Gilead's exposure to cell therapy in oncology.

http://www.gilead.com


GILD $63.77 -1.15 (-1.77%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 82.17 Billion
EPS 0.01 P/E Ratio 55.20
Previous Earnings Thu, Oct 25, 2018
Latest Earnings Mon, Feb 4, 2019
Dividend 3.58% / $2.28
Ex-Date Thu, Dec 13, 2018
Dividend Pay Date Fri, Dec 28, 2018
Dividend History 15 Payments (Quarterly)

63.77 82.17 55.20 3.58 GILD NASDAQ -1.77 0.52 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=GILD&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=GILD&exchange=NASDAQ&chart=1

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant, which Eli Lilly licenses, and oncology drug Iclusig for chronic myeloid leukemia. Incyte's pipeline includes a broad array of oncology and autoimmune programs, including next-generation JAK inhibitor itacitinib.

http://www.incyte.com


INCY $85.34 -1.74 (-2.00%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 18.64 Billion
EPS 0.33 P/E Ratio 167.33
Previous Earnings Tue, Oct 30, 2018
Latest Earnings Thu, Feb 14, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

85.34 18.64 167.33 0.00 INCY NASDAQ -2.00 34.27 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=INCY&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=INCY&exchange=NASDAQ&chart=1

Johnson & Johnson is the world's largest and most diverse healthcare company. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women's health. Geographically, close to half of total revenue is generated within the United States.

http://www.jnj.com


JNJ $136.91 -1.19 (-0.86%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 366.37 Billion
EPS 1.13 P/E Ratio 24.40
Previous Earnings Tue, Oct 16, 2018
Latest Earnings Tue, Jan 22, 2019
Dividend 2.63% / $3.60
Ex-Date Mon, Feb 25, 2019
Dividend Pay Date Tue, Mar 12, 2019
Dividend History 189 Payments (Quarterly)

136.91 366.37 24.40 2.63 JNJ NYSE -0.86 7.17 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=JNJ&exchange=NYSE&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=JNJ&exchange=NYSE&chart=1

Eli Lilly is a pharmaceutical company with a focus on neuroscience, endocrinology, oncology, and immunology. Lilly's key products include Alimta for cancer; Forteo for osteoporosis; Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Cialis for erectile dysfunction. Also, Lilly holds a strong position in the animal pharmaceutical market, which it plans to divest in late 2018.

http://www.lilly.com


LLY $128.30 -0.01 (-0.01%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 124.51 Billion
EPS 1.10 P/E Ratio 41.98
Previous Earnings Wed, Feb 13, 2019
Latest Earnings Tue, Apr 30, 2019
Dividend 2.01% / $2.58
Ex-Date Thu, Feb 14, 2019
Dividend Pay Date Fri, Mar 8, 2019
Dividend History 133 Payments (Quarterly)

128.30 124.51 41.98 2.01 LLY NYSE -0.01 11.68 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=LLY&exchange=NYSE&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=LLY&exchange=NYSE&chart=1

Mallinckrodt PLC is a specialty pharmaceutical company that was spun off from Covidien and historically focused on pain therapeutics. After recently moving its generics business into discontinued operations, Mallinckrodt now focuses entirely on branded drugs following the sale of its nuclear imaging business in 2016. Mallinckrodt's products now span a number of therapeutic areas, but a significant portion focus on hospital and clinical customers.

http://www.mallinckrodt.com


MNK $22.09 -1.71 (-7.18%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 1.99 Billion
EPS -44.26 P/E Ratio 0.00
Previous Earnings Tue, Nov 6, 2018
Latest Earnings Tue, Feb 26, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

22.09 1.99 0.00 0.00 MNK NYSE -7.18 33.15 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=MNK&exchange=NYSE&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=MNK&exchange=NYSE&chart=1

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiovascular disease, asthma, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, close to half of the company's sales are generated in the United States.

https://www.merck.com


MRK $82.29 -0.66 (-0.80%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 214.11 Billion
EPS 0.70 P/E Ratio 35.47
Previous Earnings Fri, Feb 1, 2019
Latest Earnings Tue, Apr 30, 2019
Dividend 2.67% / $2.20
Ex-Date Fri, Dec 14, 2018
Dividend Pay Date Tue, Jan 8, 2019
Dividend History 133 Payments (Quarterly)

82.29 214.11 35.47 2.67 MRK NYSE -0.80 8.86 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=MRK&exchange=NYSE&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=MRK&exchange=NYSE&chart=1

Mylan is one of the world's largest generic pharmaceutical manufacturers with operations in the United States, Europe, Asia, Middle East, Africa, and Australia. Generic drug sales constitute approximately 90% of revenue. Remaining sales come from a handful of branded products, primarily epinephrine injector EpiPen. Mylan also owns Matrix, an Indian active pharmaceutical ingredient manufacturer.

http://www.mylan.com


MYL $28.69 -0.56 (-1.91%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 15.09 Billion
EPS 0.10 P/E Ratio 28.88
Previous Earnings Mon, Nov 5, 2018
Latest Earnings Tue, Feb 26, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History 73 Payments (Quarterly)

28.69 15.09 28.88 0.00 MYL NASDAQ -1.91 2.76 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=MYL&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=MYL&exchange=NASDAQ&chart=1

Pfizer is one of the world's largest pharmaceutical firms, with annual sales over $50 billion. Pfizer also spends a leading amount on research and development, close to $8 billion annually. While Pfizer historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, neuroscience drug Lyrica, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drugs Enbrel and Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor, representing over a fifth of total company sales.

http://www.pfizer.com


PFE $41.85 -0.50 (-1.18%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 235.12 Billion
EPS -0.06 P/E Ratio 11.28
Previous Earnings Tue, Oct 30, 2018
Latest Earnings Tue, Jan 29, 2019
Dividend 3.44% / $1.44
Ex-Date Thu, Jan 31, 2019
Dividend Pay Date Fri, Mar 1, 2019
Dividend History 133 Payments (Quarterly)

41.85 235.12 11.28 3.44 PFE NYSE -1.18 -3.24 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=PFE&exchange=NYSE&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=PFE&exchange=NYSE&chart=1

Perrigo is the largest store-brand over-the-counter pharmaceutical and infant formula manufacturer. The company operates three major segments: consumer healthcare, branded consumer healthcare, and prescription pharmaceuticals. As of mid-2018, Perrigo plans to divest the prescription segment. In the United States, Perrigo sells about 2,100 products with 9,000 stock-keeping units. Following the acquisition of Omega Pharma, approximately 30% of the company's revenue comes from outside the U.S.

https://www.perrigo.com


PRGO $47.25 -1.33 (-2.74%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 6.60 Billion
EPS 0.59 P/E Ratio 67.25
Previous Earnings Thu, Aug 9, 2018
Latest Earnings Thu, Nov 8, 2018
Dividend 1.61% / $0.76
Ex-Date Thu, Feb 28, 2019
Dividend Pay Date Tue, Mar 19, 2019
Dividend History 65 Payments (Quarterly)

47.25 6.60 67.25 1.61 PRGO NYSE -2.74 16.67 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=PRGO&exchange=NYSE&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=PRGO&exchange=NYSE&chart=1

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has six marketed products: Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Zaltrap in colorectal cancer; Dupixent in atopic dermatitis and asthma; Libtayo in cutaneous squamous cell carcinoma; Arcalyst in CAPS; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal antibodies with Sanofi in immunology and cancer.

http://www.regeneron.com


REGN $391.80 -10.79 (-2.68%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 43.99 Billion
EPS 7.59 P/E Ratio 24.20
Previous Earnings Tue, Nov 6, 2018
Latest Earnings Wed, Feb 6, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

391.80 43.99 24.20 0.00 REGN NASDAQ -2.68 5.20 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=REGN&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=REGN&exchange=NASDAQ&chart=1

Vertex Pharmaceuticals discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, and Symdeko for cystic fibrosis, in addition to several mid- and late-stage products targeting this market. Vertex successfully developed and commercialized two HIV protease inhibitors, which were outlicensed to GlaxoSmithKline. Vertex's pipeline also includes therapies for the treatment of cancer, pain, inflammatory diseases, influenza, and other rare diseases.

http://www.vrtx.com


VRTX $181.53 -1.03 (-0.56%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 46.67 Billion
EPS 6.09 P/E Ratio 22.44
Previous Earnings Wed, Oct 24, 2018
Latest Earnings Tue, Feb 5, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

181.53 46.67 22.44 0.00 VRTX NASDAQ -0.56 10.64 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=VRTX&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=VRTX&exchange=NASDAQ&chart=1

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns more than 55% of total revenue from production animals (cattle, pigs, poultry, and so on), and companion animal (dogs, horses, cats) products make up the remainder. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

http://www.zoetis.com


ZTS $97.93 -1.71 (-1.72%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 47.70 Billion
EPS 0.72 P/E Ratio 33.42
Previous Earnings Thu, Nov 1, 2018
Latest Earnings Thu, Feb 14, 2019
Dividend 0.67% / $0.66
Ex-Date Wed, Apr 17, 2019
Dividend Pay Date Mon, Jun 3, 2019
Dividend History 25 Payments (Quarterly)

97.93 47.70 33.42 0.67 ZTS NYSE -1.72 15.92 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ZTS&exchange=NYSE&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ZTS&exchange=NYSE&chart=1

Shire is a diversified, Ireland-based specialty drug firm. Shire has grown primarily through mergers and acquisitions, including the Transkaryotic Therapies acquisition in 2005, which established its genetic disease business with Replagal and Elaprase, and the merger with New River in 2007, which brought full rights to neuroscience drug Vyvanse. Shire completed the acquisition of ViroPharma (genetic diseases) in 2014, NPS Pharma (internal medicine) in 2015, and Baxalta (hematology, immunology, and oncology) and Dyax (genetic diseases) in 2016.

http://www.shire.com


SHPG $179.20 0.00 (0.00%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 33.15 Billion
EPS 1.77 P/E Ratio 11.36
Previous Earnings Tue, Jul 31, 2018
Latest Earnings Thu, Nov 1, 2018
Dividend 0.19% / $0.17
Ex-Date Thu, Sep 6, 2018
Dividend Pay Date Fri, Oct 19, 2018
Dividend History --

179.20 33.15 11.36 0.19 SHPG NASDAQ 0.00 3.76 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=SHPG&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=SHPG&exchange=NASDAQ&chart=1

Nektar Therapeutics is a San Francisco-based emerging biotechnology company specializing in PEGylation technology. Its portfolio includes PEGylated biologics in immuno-oncology, chronic pain, hemophilia, breast cancer, and autoimmune disease. The company partners with several large pharmaceutical and biotechnology companies to co-develop therapies in a range of indications, which includes a collaboration with Bristol-Myers Squibb to develop NKTR-214, the firm's leading immuno-oncology candidate, in combination with Bristol's Opdivo.

http://www.nektar.com


NKTR $32.17 -1.31 (-3.91%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 5.83 Billion
EPS -0.61 P/E Ratio 8.51
Previous Earnings Wed, Nov 7, 2018
Latest Earnings Thu, Feb 28, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

32.17 5.83 8.51 0.00 NKTR NASDAQ -3.91 -5.99 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=NKTR&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=NKTR&exchange=NASDAQ&chart=1

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. The company offers a diverse array of drugs with its highest revenue generator, Lantus, representing just under 10% of total sales. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of sales.

http://www.sanofi.com


SNY $45.02 +0.11 (0.24%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 111.69 Billion
EPS 0.10 P/E Ratio 22.47
Previous Earnings Thu, Feb 7, 2019
Latest Earnings Fri, Apr 26, 2019
Dividend 4.20% / $1.86
Ex-Date Wed, May 9, 2018
Dividend Pay Date Mon, Jun 4, 2018
Dividend History 18 Payments (Annually)

45.02 111.69 22.47 4.20 SNY NYSE 0.24 5.04 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=SNY&exchange=NYSE&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=SNY&exchange=NYSE&chart=1

Headquartered in Israel, Teva Pharmaceutical is one of the world's largest generic pharmaceutical manufacturers. The company also develops and sells branded pharmaceuticals in central nervous system, oncology, and respiratory categories. Teva's generic drug sales represent about 55% of total revenue, with branded drug and distribution revenue making up the balance of sales. Prior to generic competition, Copaxone made up about half of Teva's branded drug segment, with about $4 billion in annual sales.

http://www.tevapharm.com


TEVA $16.33 -0.75 (-4.39%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 18.61 Billion
EPS -2.88 P/E Ratio 0.00
Previous Earnings Thu, Nov 1, 2018
Latest Earnings Wed, Feb 13, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History 132 Payments (Quarterly)

16.33 18.61 0.00 0.00 TEVA NYSE -4.39 3.03 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=TEVA&exchange=NYSE&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=TEVA&exchange=NYSE&chart=1

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. The gene therapy involves the use of DNA as a potential therapy to treat a disease. The company's initial programs are focused on lysosomal storage diseases such as Mucopolysaccharidosis (MPS) IIIA and IIIB. It is also developing ABO-202 and ABO-201, which are AAV-based gene therapies for the CLN1 and CLN3 forms of Batten Disease, respectively, ABO-401 for the treatment of cystic fibrosis, and ABO-5OX for the treatment of retinal diseases.

http://www.abeonatherapeutics.com


ABEO $7.52 -0.79 (-9.51%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 360 Million
EPS -0.42 P/E Ratio 0.00
Previous Earnings Fri, Nov 9, 2018
Latest Earnings Mon, Mar 18, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

7.52 0.36 0.00 0.00 ABEO NASDAQ -9.51 6.97 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ABEO&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ABEO&exchange=NASDAQ&chart=1

ARCA biopharma Inc is a biopharmaceutical company. It applies precision medicine approach to develop genetically targeted therapies for cardiovascular diseases. The firm's lead product candidate is Gencaro. The company adopts genotype-directed comparative effectiveness trial of Bucindolol and Toprol-XL for prevention of symptomatic atrial fibrillation in patients with heart failure. It establishes long-term relationships with partners such as Medtronic, Laboratory Corporation of America and the University of Colorado.

http://www.arcabiopharma.com


ABIO $0.39 -0.02 (-4.88%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 10 Million
EPS -0.10 P/E Ratio 0.00
Previous Earnings --
Latest Earnings --
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

0.39 0.01 0.00 0.00 ABIO NASDAQ -4.88 18.18 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ABIO&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ABIO&exchange=NASDAQ&chart=1

Arbutus Biopharma Corp is a pharmaceutical company. It discovers, develops and commercializes cure for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and also involved in licensing of Lipid nanoparticle technology.

http://www.arbutusbio.com


ABUS $3.53 -0.17 (-4.59%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 210 Million
EPS -0.37 P/E Ratio 0.00
Previous Earnings Wed, Nov 7, 2018
Latest Earnings Thu, Mar 7, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

3.53 0.21 0.00 0.00 ABUS NASDAQ -4.59 -11.75 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ABUS&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ABUS&exchange=NASDAQ&chart=1

Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

http://www.acadia-pharm.com


ACAD $26.10 -1.12 (-4.11%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 3.77 Billion
EPS -0.50 P/E Ratio 0.00
Previous Earnings Tue, Nov 6, 2018
Latest Earnings Tue, Feb 26, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

26.10 3.77 0.00 0.00 ACAD NASDAQ -4.11 56.76 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ACAD&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ACAD&exchange=NASDAQ&chart=1

Acer Therapeutics Inc operates as a pharmaceutical company. Principally, it is focused on the acquisition, development, and commercialization of therapies for patients with serious rare and ultra-rare diseases with a critical unmet medical need. The company's clinical pipeline includes two categories of severe genetic disorders namely EDSIVO for vEDS, and ACER-001 for urea cycle disorders and maple syrup urine disease.

https://www.acertx.com


ACER $22.90 -0.61 (-2.59%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 240 Million
EPS -0.90 P/E Ratio 0.00
Previous Earnings Fri, Nov 9, 2018
Latest Earnings Thu, Mar 7, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

22.90 0.24 0.00 0.00 ACER NASDAQ -2.59 6.76 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ACER&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ACER&exchange=NASDAQ&chart=1

Achillion Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on advancing oral small molecule complement system inhibitors into late-stage development and commercialization.

http://www.achillion.com


ACHN $2.93 -0.20 (-6.39%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 430 Million
EPS -0.12 P/E Ratio 0.00
Previous Earnings Wed, Nov 7, 2018
Latest Earnings Thu, Mar 7, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

2.93 0.43 0.00 0.00 ACHN NASDAQ -6.39 73.37 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ACHN&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ACHN&exchange=NASDAQ&chart=1

Achieve Life Sciences Inc is a United States based clinical-stage biopharmaceutical company. It is focused on the development of novel next-generation cancer therapeutics. The company's product candidate is apatorsen which is designed to block the production of heat shock protein 27, or Hsp27, a protein that promotes treatment resistance in cancer. The group has business offices located in Bothell, Washington and Vancouver, British Columbia.

http://www.achievelifesciences.com


ACHV $2.83 -0.15 (-5.03%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 20 Million
EPS 0.09 P/E Ratio 0.72
Previous Earnings --
Latest Earnings --
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

2.83 0.02 0.72 0.00 ACHV NASDAQ -5.03 121.09 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ACHV&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ACHV&exchange=NASDAQ&chart=1

AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding.

http://www.acimmune.com


ACIU $4.76 +0.26 (5.78%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 300 Million
EPS -0.21 P/E Ratio 0.00
Previous Earnings Wed, Aug 8, 2018
Latest Earnings Tue, Nov 13, 2018
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

4.76 0.30 0.00 0.00 ACIU NASDAQ 5.78 -53.42 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ACIU&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ACIU&exchange=NASDAQ&chart=1

Acorda Therapeutics is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders.Acorda uses scientific, clinical, and commercial expertise in neurology as strategic points of access in additional nervous system markets, including stroke, Parkinson's disease, and epilepsy. The company does not operate separate lines of business with respect to any of its products or product candidates. All of its net product revenue is derived from the United States.

http://www.acorda.com


ACOR $13.13 -0.92 (-6.55%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 650 Million
EPS 0.21 P/E Ratio 0.00
Previous Earnings Wed, Oct 31, 2018
Latest Earnings Thu, Feb 14, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

13.13 0.65 0.00 0.00 ACOR NASDAQ -6.55 -19.05 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ACOR&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ACOR&exchange=NASDAQ&chart=1

Aclaris Therapeutics Inc is a clinical-stage specialty pharmaceutical company which operates in United States. It focuses on identifying, developing and commercializing differentiated drugs to address significant unmet needs in dermatology. The company holds a drug candidate, A-101 Topical Solution which is a proprietary high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis (SK) a common non-malignant skin tumor. Its pipeline of drug candidates includes A-101 as a Topical Solution for treatment of SK, common warts; A-102 as a gel dosage form for treatment of SK and warts and A-201 and A-301 as an oral and topical formulation for treatment of autoimmune dermatologic respectively.

http://www.aclaristx.com


ACRS $6.12 -0.15 (-2.39%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 260 Million
EPS -0.99 P/E Ratio 0.00
Previous Earnings Tue, Nov 6, 2018
Latest Earnings Mon, Mar 18, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

6.12 0.26 0.00 0.00 ACRS NASDAQ -2.39 -20.10 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ACRS&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ACRS&exchange=NASDAQ&chart=1

Acasti Pharma Inc is a biopharmaceutical company operating in Canada. It focuses on the research, development, and commercialization of prescription drugs using omega-3 fatty acids derived from krill oil. The key product candidate of the company, CaPre is developed for the treatment of severe hypertriglyceridemia, which is a condition characterized by abnormally high levels of triglycerides in the bloodstream. The company operates through the single segment being Development and commercialization of prescription drugs.

http://www.acastipharma.com


ACST $1.05 -0.02 (-1.87%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 80 Million
EPS -0.07 P/E Ratio 0.00
Previous Earnings Wed, Nov 14, 2018
Latest Earnings Thu, Feb 14, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

1.05 0.08 0.00 0.00 ACST NASDAQ -1.87 16.67 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ACST&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ACST&exchange=NASDAQ&chart=1

Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A10 T-cell therapy, NON-SMALL CELL LUNG CANCER, AFP SPEAR T-cell, MAGE-A4 SPEAR T-cell therapy and NY-ESO SPEAR T-cell for multiple cancer types.

http://www.adaptimmune.com


ADAP $3.63 -0.20 (-5.22%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 400 Million
EPS -0.36 P/E Ratio 0.00
Previous Earnings Tue, Nov 6, 2018
Latest Earnings Wed, Feb 27, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

3.63 0.40 0.00 0.00 ADAP NASDAQ -5.22 -34.48 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ADAP&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ADAP&exchange=NASDAQ&chart=1

Adial Pharmaceuticals Inc is a United States-based pharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is an approved drug for treating nausea and emesis.

http://www.adialpharma.com


ADIL $3.01 -0.10 (-3.22%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 30 Million
EPS 0.07 P/E Ratio 0.00
Previous Earnings --
Latest Earnings --
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

3.01 0.03 0.00 0.00 ADIL NASDAQ -3.22 -53.69 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ADIL&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ADIL&exchange=NASDAQ&chart=1

ADMA BIOLOGICS INC
ADMA $3.31 -0.19 (-5.43%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 230 Million
EPS -0.39 P/E Ratio 0.00
Previous Earnings Thu, Nov 8, 2018
Latest Earnings Wed, Mar 13, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

3.31 0.23 0.00 0.00 ADMA NASDAQ -5.43 26.34 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ADMA&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ADMA&exchange=NASDAQ&chart=1

Aduro Biotech Inc is a immunotherapy company focused on the discovery, development and commercialization of therapies that are designed to harness the body's natural immune system for the treatment of patients with challenging diseases. Its primary technologies related are to the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand. The STING pathway activator technology is designed to activate the intracellular STING receptor. The APRIL is a soluble factor that binds to BCMA and TACI receptors thereby inducing signaling, and is implicated in IgA nephropathy.

http://www.aduro.com


ADRO $3.67 -0.20 (-5.17%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 310 Million
EPS -0.33 P/E Ratio 0.00
Previous Earnings Tue, Oct 30, 2018
Latest Earnings Wed, Feb 27, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

3.67 0.31 0.00 0.00 ADRO NASDAQ -5.17 34.43 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ADRO&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ADRO&exchange=NASDAQ&chart=1

Adverum Biotechnologies Inc is a US-based clinical-stage gene therapy company. The company is committed to discovering and developing novel medicines that can offer potentially life-changing therapeutic benefit to patients living with rare diseases or diseases of the eye, who currently have limited or burdensome treatment options. Its services are focused on advancing three lead gene therapy programs to address unmet needs in wet age-related macular degeneration and in rare diseases alpha-1 antitrypsin deficiency and hereditary angioedema. Its leading programs include ADVM-022, ADVM-043 and ADVM-053.

http://www.adverum.com


ADVM $5.51 -0.51 (-8.47%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 350 Million
EPS -0.24 P/E Ratio 0.00
Previous Earnings Thu, Nov 8, 2018
Latest Earnings Wed, Mar 6, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

5.51 0.35 0.00 0.00 ADVM NASDAQ -8.47 61.58 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ADVM&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ADVM&exchange=NASDAQ&chart=1

ADVAXIS INC
ADXS $0.48 -0.01 (-2.04%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 30 Million
EPS 0.18 P/E Ratio 0.00
Previous Earnings Tue, Jan 15, 2019
Latest Earnings Tue, Mar 12, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

0.48 0.03 0.00 0.00 ADXS NASDAQ -2.04 60.00 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ADXS&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ADXS&exchange=NASDAQ&chart=1

AEterna Zentaris Inc is a specialty biopharmaceutical company. It is involved in development and commercialization of novel pharmaceutical therapies, drug development activities and promotion of products for others in oncology, endocrinology and women's health. The company focuses on the acquisition of licenses to products that are relevant to their therapeutic areas of focus. Its primary product is Apifiny. It is developing Macrilen, Zoptrex and AEZS drugs in the pipeline.

http://www.aezsinc.com


AEZS $4.14 -0.13 (-3.04%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 70 Million
EPS -0.15 P/E Ratio 5.30
Previous Earnings Thu, Aug 9, 2018
Latest Earnings Tue, Nov 6, 2018
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

4.14 0.07 5.30 0.00 AEZS NASDAQ -3.04 36.63 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AEZS&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AEZS&exchange=NASDAQ&chart=1

AFFIMED NV
AFMD $4.00 -0.18 (-4.31%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 270 Million
EPS -0.19 P/E Ratio 0.00
Previous Earnings Wed, Nov 7, 2018
Latest Earnings Wed, Mar 27, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

4.00 0.27 0.00 0.00 AFMD NASDAQ -4.31 24.22 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AFMD&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AFMD&exchange=NASDAQ&chart=1

Agenus Inc is an American biotechnology company. Its main target is immuno-oncology treatments. The company's portfolio consists of therapeutic antibodies and vaccines to treat immuno-oncology illnesses: cancers, shingles, malaria, glioblastoma, and others. Agenus treatments aim, by combining multiple antibody platforms, to stimulate the immune system to recognize and fight cancer cells. The company has been cooperating with companies like Incyte, Merck Sharp & Dohme, and Recepta Biopharma to achieve over a dozen antibody programs. Some of its products include Prophage, AutoSynVax, QS-21 Stimulon, and others.

http://www.agenusbio.com


AGEN $2.82 -0.16 (-5.37%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 400 Million
EPS -0.29 P/E Ratio 0.00
Previous Earnings Tue, Nov 6, 2018
Latest Earnings Thu, Mar 14, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

2.82 0.40 0.00 0.00 AGEN NASDAQ -5.37 12.35 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AGEN&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AGEN&exchange=NASDAQ&chart=1

Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development strategy for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.

http://www.agios.com


AGIO $62.29 -3.30 (-5.03%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 3.83 Billion
EPS -1.58 P/E Ratio 0.00
Previous Earnings Thu, Nov 1, 2018
Latest Earnings Thu, Feb 14, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

62.29 3.83 0.00 0.00 AGIO NASDAQ -5.03 31.83 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AGIO&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AGIO&exchange=NASDAQ&chart=1

Aeglea BioTherapeutics Inc is a clinical-stage biotechnology company. It designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in an early clinical development stage.

https://www.aegleabio.com


AGLE $7.75 -0.43 (-5.26%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 240 Million
EPS -0.64 P/E Ratio 0.00
Previous Earnings Thu, Nov 8, 2018
Latest Earnings Thu, Mar 7, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

7.75 0.24 0.00 0.00 AGLE NASDAQ -5.26 -3.61 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AGLE&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AGLE&exchange=NASDAQ&chart=1

Applied Genetic Technologies Corp is a clinical-stage biotechnology company that uses a proprietary gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. Its initial focus is in the field of ophthalmology, where it has active clinical trials in X-linked retinitis pigmentosa, achromatopsia (ACHM CNGB3 & ACHM CNGA3), and X-linked retinoschisis. In addition to its clinical trials, company has preclinical programs in optogenetics, adrenoleukodystrophy, which is a disease of the central nervous system, other ophthalmology and otology indications. The optogenetics program is being developed in collaboration with Bionic Sight.

http://www.agtc.com


AGTC $4.17 -0.27 (-6.08%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 80 Million
EPS -0.23 P/E Ratio 0.00
Previous Earnings Thu, Nov 8, 2018
Latest Earnings Thu, Feb 7, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

4.17 0.08 0.00 0.00 AGTC NASDAQ -6.08 57.36 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AGTC&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AGTC&exchange=NASDAQ&chart=1

Aimmune Therapeutics Inc is a company operating in the United States biotechnology industry. Its main focus is in the development of product candidates to combat peanut and other food allergies. The company's therapeutic approach, which is referred to as Characterized Oral Desensitization Immunotherapy, is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols, and support services.

https://www.aimmune.com


AIMT $21.48 -0.59 (-2.67%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 1.32 Billion
EPS -0.95 P/E Ratio 0.00
Previous Earnings Thu, Nov 8, 2018
Latest Earnings Thu, Feb 28, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

21.48 1.32 0.00 0.00 AIMT NASDAQ -2.67 -11.75 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AIMT&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AIMT&exchange=NASDAQ&chart=1

Achaogen Inc is a biopharmaceutical company developing novel antibacterial treatments against multi-drug resistant gram-negative infections. The company is researching and developing on its product plazomicin used for the treatment of serious bacterial infections. It's another antibacterial candidate, C-Scape treats patients with urinary tract infections. All of the company's revenue is generated from government contracts for research and development in the United States.

http://www.achaogen.com


AKAO $0.52 -0.04 (-7.14%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 40 Million
EPS -0.92 P/E Ratio 0.00
Previous Earnings Mon, Aug 6, 2018
Latest Earnings Thu, Nov 8, 2018
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

0.52 0.04 0.00 0.00 AKAO NASDAQ -7.14 -58.73 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AKAO&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AKAO&exchange=NASDAQ&chart=1

Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is vadadustat, an oral therapy, which is used for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. The company is also developing a HIF-based portfolio of product for the treatment of anemia. Geographically, all the business activity is functioned through the region of United States.

http://www.akebia.com


AKBA $8.39 -0.31 (-3.56%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 1.01 Billion
EPS -0.76 P/E Ratio 0.00
Previous Earnings Wed, Aug 8, 2018
Latest Earnings Thu, Nov 8, 2018
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

8.39 1.01 0.00 0.00 AKBA NASDAQ -3.56 44.66 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AKBA&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AKBA&exchange=NASDAQ&chart=1

Akcea Therapeutics Inc is a late stage biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. It is advancing a mature pipeline of novel drugs with the potential to treat multiple diseases. The company's drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc. Its most advanced drug, volanesorsen, has completed a Phase 3 clinical program for the treatment of familial chylomicronemia syndrome, or FCS, and is currently in Phase 3 clinical development for the treatment of familial partial lipodystrophy, or FPL.

https://www.akceatx.com


AKCA $27.85 -1.59 (-5.40%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 2.59 Billion
EPS -0.81 P/E Ratio 0.00
Previous Earnings Mon, Nov 5, 2018
Latest Earnings Tue, Feb 26, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

27.85 2.59 0.00 0.00 AKCA NASDAQ -5.40 -9.37 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AKCA&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AKCA&exchange=NASDAQ&chart=1

Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing inhibitors of acute and chronic inflammation which includes the complement system, the bioamine system and the eicosanoid system for the treatment of rare and orphan diseases. Its main product candidate includes Coversin, Coversin long acting and Coversin dual action. The firm earns majority of its revenues from United Kingdom. It operates mainly in United States and United Kingdom.

http://www.akaritx.com


AKTX $4.10 +0.04 (0.99%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 60 Million
EPS -0.24 P/E Ratio 0.00
Previous Earnings Thu, Sep 27, 2018
Latest Earnings Thu, Nov 15, 2018
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

4.10 0.06 0.00 0.00 AKTX NASDAQ 0.99 145.51 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AKTX&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AKTX&exchange=NASDAQ&chart=1

Albireo Pharma Inc is a development-stage pharmaceutical company. It engages in the research and development of drug reformulation technology. The company product portfolio includes Pediatric Liver, Adult Liver, and Gastrointestinal.

http://www.albireopharma.com


ALBO $28.40 -1.67 (-5.55%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 370 Million
EPS -1.34 P/E Ratio 0.00
Previous Earnings Tue, Nov 13, 2018
Latest Earnings Thu, Mar 7, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

28.40 0.37 0.00 0.00 ALBO NASDAQ -5.55 17.70 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ALBO&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ALBO&exchange=NASDAQ&chart=1

Alder BioPharmaceuticals Inc is a biotechnology company that seeks to discover, develop, and commercialize therapeutic antibodies. The company's antibody platform seeks to maximize efficacy, as well as the speed of onset and durability of therapeutic response. Alder's product pipeline addresses diseases where patients have limited medical options or where current medical options may not meet the needs of a substantial number of patients. The company operates in three geographic regions: the United States, Australia, and Ireland. The vast majority of the Alder's assets are located in the United States, where the vast majority of its revenue is also generated.

http://www.alderbio.com


ALDR $12.95 -1.36 (-9.50%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 1.00 Billion
EPS -1.19 P/E Ratio 0.00
Previous Earnings Mon, Nov 5, 2018
Latest Earnings Mon, Feb 25, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

12.95 1.00 0.00 0.00 ALDR NASDAQ -9.50 18.59 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ALDR&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ALDR&exchange=NASDAQ&chart=1

Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye diseases, allergic conjunctivities, noninfectious anterior uveitis, and Sjogren-Larsson Syndrome. The company is also developing other product candidates for proliferative vitreoretinopathy and other retinal disease, post-transplant lymphoproloferative disease, autoimmune disease, metabolic disease, and cancer. None of Aldeyra's product candidates have been approved for sale in the U.S. or elsewhere.

https://www.aldeyra.com


ALDX $7.45 -0.46 (-5.82%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 220 Million
EPS -0.39 P/E Ratio 0.00
Previous Earnings Wed, Nov 14, 2018
Latest Earnings Fri, Mar 8, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

7.45 0.22 0.00 0.00 ALDX NASDAQ -5.82 -12.46 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ALDX&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ALDX&exchange=NASDAQ&chart=1

Alkermes PLC is a fully integrated global biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in major therapeutic areas. The company utilizes several collaborative arrangements to develop and commercialize products and, in so doing, to access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies.

http://www.alkermes.com


ALKS $33.96 -0.98 (-2.80%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 5.45 Billion
EPS -0.06 P/E Ratio 0.00
Previous Earnings Tue, Oct 23, 2018
Latest Earnings Thu, Feb 14, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

33.96 5.45 0.00 0.00 ALKS NASDAQ -2.80 16.66 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ALKS&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ALKS&exchange=NASDAQ&chart=1

Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK002, an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. In preclinical and clinical studies, AK002 has been shown to deplete eosinophils and inhibit mast cells.

https://www.allakos.com


ALLK $36.30 -1.72 (-4.52%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 1.64 Billion
EPS 0.14 P/E Ratio 0.00
Previous Earnings Thu, Nov 8, 2018
Latest Earnings Thu, Mar 14, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

36.30 1.64 0.00 0.00 ALLK NASDAQ -4.52 -30.18 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ALLK&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ALLK&exchange=NASDAQ&chart=1

Allogene Therapeutics Inc is the United States-based clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies.

https://www.allogene.com


ALLO $25.55 -1.73 (-6.34%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 3.31 Billion
EPS -0.25 P/E Ratio 0.00
Previous Earnings --
Latest Earnings --
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

25.55 3.31 0.00 0.00 ALLO NASDAQ -6.34 -7.29 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ALLO&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ALLO&exchange=NASDAQ&chart=1

Allena Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. The company is focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease. The company's product candidate, reloxaliase, is a first-in-class, oral enzyme therapeutic for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, CKD and other serious kidney diseases.

http://www.allenapharma.com


ALNA $6.97 -0.10 (-1.41%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 150 Million
EPS -0.46 P/E Ratio 0.00
Previous Earnings Wed, Nov 7, 2018
Latest Earnings Thu, Mar 7, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

6.97 0.15 0.00 0.00 ALNA NASDAQ -1.41 8.40 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ALNA&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ALNA&exchange=NASDAQ&chart=1

Alnylam Pharmaceuticals is a leader in the study of RNA interference and is attempting to harness this mechanism to create a new class of drugs. In addition to FDA-approved patisiran for amyloidosis, Alnylam has partnered several pipeline candidates, including hemophilia drug fitusiran, and cholesterol drug inclisiran. Up-front fees from research partnerships with firms such as Sanofi, Takeda, Roche, and The Medicines Company have boosted Alnylam's cash levels, and the company stands to see milestones and royalties from drugs commercialized under these agreements.

http://www.alnylam.com


ALNY $84.52 -6.22 (-6.85%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 9.64 Billion
EPS -2.09 P/E Ratio 0.00
Previous Earnings Wed, Nov 7, 2018
Latest Earnings Thu, Feb 7, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

84.52 9.64 0.00 0.00 ALNY NASDAQ -6.85 16.16 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ALNY&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ALNY&exchange=NASDAQ&chart=1

Alpine Immune Sciences Inc is engaged in discovering and developing modern, protein-based immunotherapies targeting the immune synapse to treat cancer, inflammation, and other diseases. The company's proprietary scientific platform uses a process known as directed evolution to create therapeutics potentially capable of modulating human immune system proteins.

https://www.alpineimmunesciences.com


ALPN $6.85 +0.03 (0.44%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 130 Million
EPS -0.88 P/E Ratio 0.00
Previous Earnings Thu, Aug 9, 2018
Latest Earnings Thu, Nov 8, 2018
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

6.85 0.13 0.00 0.00 ALPN NASDAQ 0.44 67.48 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ALPN&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ALPN&exchange=NASDAQ&chart=1

Aileron Therapeutics Inc a clinical-stage biopharmaceutical company. It is focused on developing and commercializing a novel class of therapeutics called stapled peptides. Its lead product candidate, ALRN-6924, targets the tumor suppressor p53 for the treatment of a wide variety of cancers. ALRN-6924, reactivates p53-mediated tumor suppression by targeting the two primary p53 suppressor proteins, MDMX and MDM2.

http://www.aileronrx.com


ALRN $1.94 +0.01 (0.52%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 30 Million
EPS -0.50 P/E Ratio 0.00
Previous Earnings Tue, Aug 7, 2018
Latest Earnings Wed, Nov 7, 2018
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

1.94 0.03 0.00 0.00 ALRN NASDAQ 0.52 90.20 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ALRN&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ALRN&exchange=NASDAQ&chart=1

Altimmune Inc is a clinical stage immunotherapeutic biotechnology company. It is involved in the business of developing products that engage, stimulate and improve immune responses for the prevention and treatment of diseases. The firm's product candidates include Nasovax, Heptcell, Sparvax-L, Nasoshield, and Oncosyn. It also develops platform technologies such as RespirVec and Densigen. The company generates its revenue from cost plus fee contracts and fixed-price contracts.

http://www.altimmune.com


ALT $2.84 -0.16 (-5.33%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 30 Million
EPS -1.73 P/E Ratio 0.00
Previous Earnings --
Latest Earnings --
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History 9 Payments (Quarterly)

2.84 0.03 0.00 0.00 ALT NASDAQ -5.33 9.23 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ALT&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ALT&exchange=NASDAQ&chart=1

AMAG Pharmaceuticals Inc primarily uses its nanoparticle technology to develop therapeutic compounds to treat anemia in patients suffering from chronic kidney disease, as well as imaging agents that assist in identifying cancerous tumors. The company recently received Food and Drug Administration approval for Feraheme, a novel iron replacement drug for CKD patients suffering from anemia, and also offers GastroMARK, an imaging aid used with magnetic resonance imaging. Most of the revenues are generated through the sale of Feraheme and Makena which is a hydroxyprogesterone caproate injection.

http://www.amagpharma.com


AMAG $12.16 -0.55 (-4.33%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 420 Million
EPS -0.64 P/E Ratio 0.00
Previous Earnings Thu, Nov 1, 2018
Latest Earnings Thu, Feb 7, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

12.16 0.42 0.00 0.00 AMAG NASDAQ -4.33 -22.74 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AMAG&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AMAG&exchange=NASDAQ&chart=1

Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular health. Its products include Vascepa. The firm has Development and Commercialization of Vascepa operating segment. It mainly operates in the United States.

http://www.amarincorp.com


AMRN $17.51 -1.25 (-6.66%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 5.77 Billion
EPS -0.11 P/E Ratio 0.00
Previous Earnings Thu, Nov 1, 2018
Latest Earnings Wed, Feb 27, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

17.51 5.77 0.00 0.00 AMRN NASDAQ -6.66 34.59 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AMRN&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AMRN&exchange=NASDAQ&chart=1

AnaptysBio Inc is a US-based clinical-stage biotechnology company. It is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company develops product candidates to address emerging biological targets using its proprietary, antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product candidates are ANB020, ANB019, and Checkpoint receptor agonist. The entity generates revenue from the collaborative research and development arrangements.

http://www.anaptysbio.com


ANAB $71.17 -4.22 (-5.60%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 1.92 Billion
EPS -0.64 P/E Ratio 0.00
Previous Earnings Thu, Nov 8, 2018
Latest Earnings Thu, Feb 28, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

71.17 1.92 0.00 0.00 ANAB NASDAQ -5.60 11.69 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ANAB&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ANAB&exchange=NASDAQ&chart=1

Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company's product profile includes Orthobiologics, Dermal, Surgical and other of which Orthobiologics products generates maximum revenue to the company.

http://www.anikatherapeutics.com


ANIK $29.42 -0.66 (-2.19%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 430 Million
EPS 0.54 P/E Ratio 23.17
Previous Earnings Wed, Oct 24, 2018
Latest Earnings Thu, Feb 21, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

29.42 0.43 23.17 0.00 ANIK NASDAQ -2.19 -14.77 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ANIK&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ANIK&exchange=NASDAQ&chart=1

ANI Pharmaceuticals Inc develops, manufactures and markets generic prescription pharmaceuticals, made in the U.S.A. It manufactures liquid, powder and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Its generic products include Erythromycin Ethylsuccinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup Nilutamide, Nimodipine, Opium Tincture, Oxycodone Capsules, Oxycodone Oral Solution, Propafenone, and Vancomycin.

http://www.anipharmaceuticals.com


ANIP $65.97 +1.55 (2.41%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 780 Million
EPS 0.46 P/E Ratio 50.75
Previous Earnings Tue, Nov 6, 2018
Latest Earnings Wed, Feb 27, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

65.97 0.78 50.75 0.00 ANIP NASDAQ 2.41 43.95 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ANIP&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ANIP&exchange=NASDAQ&chart=1

Apellis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3 the central protein in the complement cascade.

http://www.apellis.com


APLS $18.90 -0.80 (-4.06%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 1.11 Billion
EPS -0.65 P/E Ratio 0.00
Previous Earnings Tue, Nov 13, 2018
Latest Earnings Tue, Feb 26, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

18.90 1.11 0.00 0.00 APLS NASDAQ -4.06 38.77 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=APLS&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=APLS&exchange=NASDAQ&chart=1

Cellect Biotechnology Ltd is a biotechnology company engaged in developing a novel technology platform. The company is engaged in the development of an innovative, unique technology that enables the biological filtering and commercialization of stem cells.

http://www.cellect.co


APOP $0.99 -0.08 (-7.48%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 10 Million
EPS -0.58 P/E Ratio 0.00
Previous Earnings Thu, Aug 9, 2018
Latest Earnings Tue, Nov 13, 2018
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

0.99 0.01 0.00 0.00 APOP NASDAQ -7.48 -57.14 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=APOP&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=APOP&exchange=NASDAQ&chart=1

Apricus Biosciences Inc is engaged in the pharmaceutical industry. The company develops and commercializes products and product candidates in the areas of urology and rheumatology. Apricus' drug delivery technology is a permeation enhancer called NexACT. The company has over two product candidates in Phase II development, fispemifene for the treatment of symptomatic male secondary hypogonadism and RayVa for the treatment of Raynaud's phenomenon.

http://www.apricusbio.com


APRI $6.60 -0.20 (-2.94%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 10 Million
EPS -0.12 P/E Ratio 0.00
Previous Earnings --
Latest Earnings Thu, Aug 9, 2018
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

6.60 0.01 0.00 0.00 APRI NASDAQ -2.94 -8.97 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=APRI&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=APRI&exchange=NASDAQ&chart=1

Aptose Biosciences Inc is a biotechnology company. It develops targeted medicines and personalized therapies for the precision treatment of life-threatening cancers such as acute myeloid leukemia, myelodysplastic syndromes and other hematologic malignancies and also therapies for Oncology. The firm has CG-806, APTO-253 drugs in preclinical development stage pipeline.

http://www.aptose.com


APTO $2.32 -0.11 (-4.53%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 100 Million
EPS -0.15 P/E Ratio 0.00
Previous Earnings Tue, Nov 6, 2018
Latest Earnings Tue, Mar 12, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

2.32 0.10 0.00 0.00 APTO NASDAQ -4.53 5.45 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=APTO&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=APTO&exchange=NASDAQ&chart=1

Aptinyx Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel, proprietary, synthetic small molecules for the treatment of brain and nervous system disorders. Its pipeline products are NYX-2925, NYX-458, and NYX-783. NYX-2925 is a novel, oral, small-molecule NMDA receptor modulator in clinical development as a therapy for chronic pain. NYX-2925 works by enhancing synaptic plasticity, a mechanism uniquely suited to addressing chronic pain, and NYX-783 is an NMDA receptor modulating small molecule in clinical development as a therapy for post-traumatic stress disorder.

https://www.aptinyx.com


APTX $4.36 +0.32 (7.92%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 140 Million
EPS -0.43 P/E Ratio 0.00
Previous Earnings Tue, Nov 13, 2018
Latest Earnings Thu, Mar 21, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

4.36 0.14 0.00 0.00 APTX NASDAQ 7.92 -74.72 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=APTX&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=APTX&exchange=NASDAQ&chart=1

Aptevo Therapeutics Inc is a biosciences company. The company is engaged in the discovery, development, commercialization and sale of novel oncology and hematology therapeutics. Its pipeline product includes Otlertuzumab, APVO414, ROR1 Candidate, Multiple ADAPTIR Candidates, ALG.APV-527, APVO436 and APVO210.

http://www.aptevotherapeutics.com


APVO $0.91 +0.07 (8.33%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 40 Million
EPS -0.62 P/E Ratio 0.00
Previous Earnings Thu, Aug 9, 2018
Latest Earnings Wed, Nov 14, 2018
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

0.91 0.04 0.00 0.00 APVO NASDAQ 8.33 -35.92 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=APVO&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=APVO&exchange=NASDAQ&chart=1

AquaBounty Technologies Inc is a biotechnology company. It is engaged in research, development, and commercialization of the commercial viability of a group of proteins, antifreeze proteins. The company primarily focuses on the managing aquaculture productivity. Its lead product is the AquAdvantage Salmon, a genetically modified animal for human consumption. Geographically, all the operation of the group is functioned through the region of US and it derives revenue from the sale of AquAdvantage Salmon.

http://www.aquabounty.com


AQB $2.28 +0.03 (1.33%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 30 Million
EPS -0.30 P/E Ratio 0.00
Previous Earnings Fri, Nov 2, 2018
Latest Earnings Thu, Mar 7, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

2.28 0.03 0.00 0.00 AQB NASDAQ 1.33 -4.60 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AQB&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AQB&exchange=NASDAQ&chart=1

Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. The product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS). Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, and Zuplenz. The products pipeline includes Exservan Oral Film, Libervant Buccal Film, AQST-119, AQST-108, and AQST-305.

https://www.aquestive.com


AQST $6.22 -0.73 (-10.50%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 160 Million
EPS -0.51 P/E Ratio 0.00
Previous Earnings Tue, Nov 6, 2018
Latest Earnings Thu, Mar 14, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

6.22 0.16 0.00 0.00 AQST NASDAQ -10.50 -13.37 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AQST&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AQST&exchange=NASDAQ&chart=1

Aravive Inc is a clinical stage biotechnology company. It focuses on developing therapies that target important survival pathways for both solid tumors as well as hematologic malignancies. The company's lead candidate AVB-S6-500 is developed as a targeted therapy against ovarian cancer.

http://www.aravive.com


ARAV $8.26 +0.42 (5.36%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 90 Million
EPS -6.41 P/E Ratio 4.57
Previous Earnings Tue, Nov 6, 2018
Latest Earnings Thu, Mar 7, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

8.26 0.09 4.57 0.00 ARAV NASDAQ 5.36 126.92 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ARAV&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ARAV&exchange=NASDAQ&chart=1

Arcturus Therapeutics Ltd is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the segment of research and development of medical applications for nucleic acid-focused technology. The product pipeline of the company includes LUNAR-OTC, LUNAR-CF and LUNAR-2020.

http://www.arcturusrx.com


ARCT $5.16 -0.33 (-6.01%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 50 Million
EPS -0.42 P/E Ratio 0.00
Previous Earnings Wed, Nov 7, 2018
Latest Earnings Mon, Mar 18, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

5.16 0.05 0.00 0.00 ARCT NASDAQ -6.01 10.02 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ARCT&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ARCT&exchange=NASDAQ&chart=1

Aridis Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is engaged in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections.

http://www.aridispharma.com


ARDS $11.59 +1.49 (14.75%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 90 Million
EPS -1.97 P/E Ratio 0.00
Previous Earnings Wed, Sep 26, 2018
Latest Earnings Tue, Nov 13, 2018
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

11.59 0.09 0.00 0.00 ARDS NASDAQ 14.75 10.38 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ARDS&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ARDS&exchange=NASDAQ&chart=1

Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of molecule and polymeric therapeutics to treat the gastrointestinal tract and cardiorenal diseases. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.

https://www.ardelyx.com


ARDX $3.35 +0.07 (2.13%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 210 Million
EPS -0.45 P/E Ratio 0.00
Previous Earnings Wed, Nov 7, 2018
Latest Earnings Wed, Mar 6, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

3.35 0.21 0.00 0.00 ARDX NASDAQ 2.13 67.50 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ARDX&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ARDX&exchange=NASDAQ&chart=1

argenx SE is a clinical stage biotechnology company. It is engaged in the business of developing a pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Its product pipeline includes product candidates such as ARGX-113, ARGX-110, ARGX-115, ARGX-112 etc. The company operates in Netherlands, Germany, Denmark, Belgium, Switzerland, United States and Luxembourg. It derives the majority of its revenues from Switzerland.

http://www.argenx.com


ARGX $125.54 -6.46 (-4.89%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 4.73 Billion
EPS -0.08 P/E Ratio 0.00
Previous Earnings --
Latest Earnings Thu, Oct 25, 2018
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

125.54 4.73 0.00 0.00 ARGX NASDAQ -4.89 27.00 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ARGX&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ARGX&exchange=NASDAQ&chart=1

Arena Pharmaceuticals is a biotechnology company targeting G-protein-coupled receptors. The company has one internally discovered drug, lorcaserin, which has been approved and is marketed in the U.S. and South Korea to target weight management. It is commercialized under the brand name Belviq. The company is collaborating with Eisai to market Belviq in other countries. It has a presence in Europe through its Swiss subsidiary, Arena GmbH. The company's pipeline contains drugs targeting autoimmune diseases, vascular diseases, thrombotic diseases, dementia-associated psychosis, nervous system issues, and pain.

http://www.arenapharm.com


ARNA $43.23 -2.43 (-5.32%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 2.14 Billion
EPS 1.49 P/E Ratio 0.00
Previous Earnings Wed, Nov 7, 2018
Latest Earnings Tue, Feb 26, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

43.23 2.14 0.00 0.00 ARNA NASDAQ -5.32 7.48 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ARNA&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ARNA&exchange=NASDAQ&chart=1

Aerpio Pharmaceuticals Inc is a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases. The company' product AKB-9778, is a Tie2 activator being developed for the treatment of diabetic eye disease. Other products under the pipeline are cc-1536 and c-4924.

http://www.aerpio.com


ARPO $1.12 +0.04 (3.70%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 50 Million
EPS -0.25 P/E Ratio 0.00
Previous Earnings Wed, Nov 7, 2018
Latest Earnings Tue, Mar 5, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

1.12 0.05 0.00 0.00 ARPO NASDAQ 3.70 -43.72 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ARPO&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ARPO&exchange=NASDAQ&chart=1

Arqule Inc is a biopharmaceutical company, engaged in the research and development of therapeutics to treat cancers and rare diseases. The objective of the company is to discover, develop and commercialize novel small molecule drugs in areas of high unmet need that will dramatically extend and improve the lives of the patients. These drugs focus on the biological pathways implicated in a range of cancers and certain non-oncology indications. Geographically, the firm operates through the region of United States.

http://www.arqule.com


ARQL $4.82 -0.32 (-6.23%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 530 Million
EPS -0.09 P/E Ratio 0.00
Previous Earnings Wed, Oct 31, 2018
Latest Earnings Thu, Mar 7, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

4.82 0.53 0.00 0.00 ARQL NASDAQ -6.23 66.78 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ARQL&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ARQL&exchange=NASDAQ&chart=1

Array BioPharma Inc is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Its clinical stage drugs include Binimetinib, Encorafenib, Selumetinib, Tucatinib/ONT-380, ARRY-382, LOXO-292 and LOXO-195 among others. The company has geographical presence in North America, Europe and Asia Pacific.

http://www.arraybiopharma.com


ARRY $22.49 -1.50 (-6.25%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 4.91 Billion
EPS -0.05 P/E Ratio 0.00
Previous Earnings Tue, Oct 30, 2018
Latest Earnings Tue, Feb 5, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

22.49 4.91 0.00 0.00 ARRY NASDAQ -6.25 50.94 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ARRY&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ARRY&exchange=NASDAQ&chart=1

Arvinas Inc, formerly Arvinas Holding Co LLC is a private biopharmaceutical company focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases. The company's proprietary PROTAC protein degraders, or Proteolysis-Targeting Chimera, work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins.

http://www.arvinas.com


ARVN $15.76 -1.13 (-6.69%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 510 Million
EPS -62.38 P/E Ratio 0.00
Previous Earnings --
Latest Earnings --
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

15.76 0.51 0.00 0.00 ARVN NASDAQ -6.69 14.12 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ARVN&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ARVN&exchange=NASDAQ&chart=1

Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.

http://www.arrowheadpharma.com


ARWR $17.77 -1.30 (-6.82%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 1.67 Billion
EPS 0.13 P/E Ratio 0.00
Previous Earnings Tue, Dec 11, 2018
Latest Earnings Thu, Feb 7, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

17.77 1.67 0.00 0.00 ARWR NASDAQ -6.82 35.44 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ARWR&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ARWR&exchange=NASDAQ&chart=1

ASLAN Pharmaceuticals Ltd is a clinical-stage oncology-focused biotechnology company. It is developing novel therapeutics for global markets. The company's portfolio consists of four product candidates which target validated growth pathways applied to new patient segments and novel cancer metabolic pathways. The company targets diseases that are both highly prevalent in Asia and orphan indications in the United States and Europe.

http://www.aslanpharma.com


ASLN $4.13 -0.25 (-5.71%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 130 Million
EPS -10.65 P/E Ratio 0.00
Previous Earnings --
Latest Earnings --
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

4.13 0.13 0.00 0.00 ASLN NASDAQ -5.71 -0.48 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ASLN&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ASLN&exchange=NASDAQ&chart=1

Assembly Biosciences Inc is a clinical stage biotechnology company. It is advancing two innovative platform programs, a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein.

http://www.assemblybio.com


ASMB $18.20 -0.80 (-4.21%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 460 Million
EPS -1.03 P/E Ratio 0.00
Previous Earnings Thu, Nov 8, 2018
Latest Earnings Thu, Feb 28, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

18.20 0.46 0.00 0.00 ASMB NASDAQ -4.21 -21.01 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ASMB&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ASMB&exchange=NASDAQ&chart=1

Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP etc. It operates mainly in USA, Germany, and Switzerland and derives the majority of its revenue from the US.

http://www.ascendispharma.com


ASND $119.07 -4.15 (-3.37%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 5.16 Billion
EPS -0.81 P/E Ratio 0.00
Previous Earnings Wed, Aug 29, 2018
Latest Earnings Wed, Nov 28, 2018
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

119.07 5.16 0.00 0.00 ASND NASDAQ -3.37 83.64 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ASND&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ASND&exchange=NASDAQ&chart=1

Arsanis Inc discovers and develops monoclonal antibodies for the targeted immunotherapy of serious infections. The company's monoclonal antibodies selectively focus on specific pathogens and pathogenic processes which address critical infections while minimizing the collateral damage from antimicrobial overuse, resistance, and microbiome disruption. Few of its products candidates are ASN100, for prevention of pneumonia in high risk, mechanically ventilated patients; ASN500, for prevention of respiratory Syncytial virus; ASN300 and ASN200, for prevention and treatment of bacterial infections.

http://www.arsanis.com


ASNS $3.11 -0.13 (-4.01%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 50 Million
EPS -0.66 P/E Ratio 0.00
Previous Earnings Mon, Aug 13, 2018
Latest Earnings Fri, Nov 9, 2018
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

3.11 0.05 0.00 0.00 ASNS NASDAQ -4.01 21.48 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ASNS&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ASNS&exchange=NASDAQ&chart=1

Athersys Inc is a clinical stage biotechnology company. It is focused on developing novel and proprietary therapies in the areas where there is significant unmet medical need, particularly in the regenerative medicine area. The firm's main product is Multistem cell therapy. Its current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders and certain pulmonary conditions. Its revenue has been derived from corporate collaborations, license agreements, and government grants.

http://www.athersys.com


ATHX $1.52 -0.10 (-6.17%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 240 Million
EPS -0.08 P/E Ratio 0.00
Previous Earnings Tue, Nov 6, 2018
Latest Earnings Thu, Mar 14, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

1.52 0.24 0.00 0.00 ATHX NASDAQ -6.17 2.70 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ATHX&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ATHX&exchange=NASDAQ&chart=1

Athenex Inc is a global biopharmaceutical company. It is dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. The company's mission is to improve the lives of cancer patients by creating more effective, safer and tolerable treatments. The company has organized its business model into three segments, Oncology Innovation Platform, Commercial Platform and Global Supply Chain Platform with operations in both the U.S. and China.

http://www.athenex.com


ATNX $12.26 -0.39 (-3.08%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 850 Million
EPS -0.41 P/E Ratio 0.00
Previous Earnings Wed, Nov 14, 2018
Latest Earnings Mon, Mar 11, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

12.26 0.85 0.00 0.00 ATNX NASDAQ -3.08 -3.99 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ATNX&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ATNX&exchange=NASDAQ&chart=1

Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing therapeutics for patients with serious life-threatening such as cancer, autoimmune and other viral diseases. The company achieves this through two groups of product candidates, such as allogenic or third-party derived antigen-specific T-cells and molecularly targeted biologics.

http://www.atarabio.com


ATRA $37.44 -2.54 (-6.35%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 1.85 Billion
EPS -1.78 P/E Ratio 0.00
Previous Earnings Tue, Nov 6, 2018
Latest Earnings Tue, Feb 26, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

37.44 1.85 0.00 0.00 ATRA NASDAQ -6.35 6.18 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ATRA&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ATRA&exchange=NASDAQ&chart=1

Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS), and Dry Eye Syndrome (DES). Geographically, it derives maximum revenue from the United States followed by China.

http://www.auriniapharma.com


AUPH $6.47 -0.28 (-4.15%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 590 Million
EPS -0.17 P/E Ratio 0.00
Previous Earnings Thu, Nov 8, 2018
Latest Earnings Tue, Mar 19, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

6.47 0.59 0.00 0.00 AUPH NASDAQ -4.15 -5.41 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AUPH&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AUPH&exchange=NASDAQ&chart=1

Autolus Therapeutics PLC is a biopharmaceutical company. It is engaged in the development of next-generation programmed T cell therapies for the treatment of cancer. The company's pipeline includes AUTO1, AUTO2, AUTO3, AUTO4, and others.

https://www.autolus.com


AUTL $24.38 -0.81 (-3.22%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 1.02 Billion
EPS -0.52 P/E Ratio 0.00
Previous Earnings --
Latest Earnings Mon, Feb 25, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

24.38 1.02 0.00 0.00 AUTL NASDAQ -3.22 -26.92 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AUTL&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AUTL&exchange=NASDAQ&chart=1

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company markets products in both the primary care and sterile injectables markets. Its products portfolio includes Bloxiverz, Vazculep (phenylephrine hydrochloride injection), Akovaz (ephedrine sulfate injection), Karbinal ER (carbinoxamine maleate extended-release oral suspension), AcipHex Sprinkle (rabeprazole sodium), Cefaclor for Oral Suspension, 125 mg/5 mL, 250 mg/5 mL and 375 mg/5 mL, and Flexichamber. Majority of the revenue is derived from the United States.

http://www.avadel.com


AVDL $1.48 -0.09 (-5.73%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 60 Million
EPS -0.24 P/E Ratio 0.00
Previous Earnings Mon, Nov 5, 2018
Latest Earnings Fri, Mar 15, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

1.48 0.06 0.00 0.00 AVDL NASDAQ -5.73 -46.76 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AVDL&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AVDL&exchange=NASDAQ&chart=1

AVEO Pharmaceuticals Inc is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted medicines for oncology and other areas of unmet medical need. The Company aim is to retain North American rights to its oncology portfolio while securing partners in development and commercialization outside of North America. It is seeking to develop and commercialize its lead candidate tivozanib in North America as a treatment for advanced or metastatic renal cell carcinoma (RCC). It has outlicensed tivozanib (FOTIVDA) for oncology in Europe and other territories outside North America. Tivozanib is approved in the European Union as well as Norway and Iceland for the first-line treatment of adult patients with RCC.

http://www.aveooncology.com


AVEO $0.58 -0.04 (-6.45%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 80 Million
EPS 0.19 P/E Ratio 0.00
Previous Earnings Fri, Nov 9, 2018
Latest Earnings Thu, Mar 14, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

0.58 0.08 0.00 0.00 AVEO NASDAQ -6.45 -68.31 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AVEO&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AVEO&exchange=NASDAQ&chart=1

Avrobio Inc is a clinical stage gene therapy company. It is engaged in the development of potentially curative ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose.

http://www.avrobio.com


AVRO $18.20 -0.83 (-4.36%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 440 Million
EPS -0.49 P/E Ratio 0.00
Previous Earnings Thu, Aug 9, 2018
Latest Earnings Tue, Nov 13, 2018
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

18.20 0.44 0.00 0.00 AVRO NASDAQ -4.36 16.29 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AVRO&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AVRO&exchange=NASDAQ&chart=1

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company operating in the United States. It is engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including drug candidates to treat Alzheimer's disease, other central nervous systems (CNS) diseases, pain and several types of cancer. The lead compound of the company is ANAVEX 2-73 which is developed to treat Alzheimer's disease, Parkinson's disease and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome. The research and development pipeline of the company includes one clinical drug candidate and several compounds in various stages of the pre-clinical study.

http://www.anavex.com


AVXL $3.08 -0.02 (-0.65%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 140 Million
EPS -0.16 P/E Ratio 0.00
Previous Earnings Wed, Dec 12, 2018
Latest Earnings Thu, Feb 7, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

3.08 0.14 0.00 0.00 AVXL NASDAQ -0.65 83.33 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AVXL&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AVXL&exchange=NASDAQ&chart=1

Axovant Sciences Ltd is a clinical-stage biopharmaceutical company focused on acquiring, developing and commercializing novel therapeutics for the treatment of dementia in the United States and Europe. It intends to develop a pipeline of product candidates to comprehensively address the cognitive, functional and behavioral aspects of dementia and related neurological disorders. The company's lead product candidate intepirdine (RVT-101) is being developed for the treatment of mild-to-moderate Alzheimer's disease and Dementia with Lewy Bodies. Intepirdine is an orally administered potent antagonist of the 5-HT6 receptor. By antagonizing the 5-HT6 receptor, intepirdine promotes the release of key neurotransmitters including acetylcholine.

http://www.axovant.com


AXON $1.22 -0.07 (-5.43%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 200 Million
EPS -0.27 P/E Ratio 0.00
Previous Earnings Wed, Nov 7, 2018
Latest Earnings Thu, Feb 7, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

1.22 0.20 0.00 0.00 AXON NASDAQ -5.43 11.93 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AXON&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AXON&exchange=NASDAQ&chart=1

Axsome Therapeutics Inc is a United States-based healthcare service provider. As a pre-clinical therapeutics developer, the company attends primarily to central nervous system disorders such as Alzheimer's. Its product portfolio consists of novel drugs like the AXS-02 (disodium zoledronate tetrahydrate), which is an oral, non-opioid therapeutic for chronic pain and the AXS-05, which is a fixed-dose combination of dextromethorphan and bupropion. The AXS-02 addresses pain in over three conditions, such as complex regional pain syndrome, knee osteoarthritis and chronic low back pain. The AXS-05 on the other hand, treats resistant depression and agitation in patients with Alzheimer's disease. Both the products have passed the preclinical, Phase 1 and Phase 2 stages of development.

https://www.axsome.com


AXSM $13.00 -0.24 (-1.81%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 400 Million
EPS -0.32 P/E Ratio 0.00
Previous Earnings Wed, Oct 17, 2018
Latest Earnings Fri, Nov 9, 2018
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

13.00 0.40 0.00 0.00 AXSM NASDAQ -1.81 385.07 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AXSM&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AXSM&exchange=NASDAQ&chart=1

Aytu BioScience Inc is a commercial-stage healthcare company focused on acquiring, developing and commercializing products in the field of urology. It focuses on hypogonadism, prostate cancer, urinary tract infections, and male infertility. The company markets ProstaScint (capromab pendetide), a radio-imaging agent indicated to detect the prostate-specific membrane antigen (PSMA) in the assessment and staging of prostate cancer. Other products of the company include MiOXSYS, a novel in vitro diagnostic device, Natesto (testosterone) nasal gel, and Fiera Personal Care Device. The company, through its wholly-owned subsidiary Nuelle, Inc, is also focused on women's sexual wellbeing and intimacy.

http://www.aytubio.com


AYTU $1.79 -0.11 (-5.79%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 20 Million
EPS -0.72 P/E Ratio 0.06
Previous Earnings --
Latest Earnings --
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

1.79 0.02 0.06 0.00 AYTU NASDAQ -5.79 123.75 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AYTU&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AYTU&exchange=NASDAQ&chart=1

AzurRx BioPharma Inc is a development stage biopharmaceutical company. The company is focused on the development of recombinant proteins for the treatment of gastrointestinal diseases and microbiome related conditions.

http://www.azurrx.com


AZRX $2.27 +0.01 (0.44%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 40 Million
EPS -0.15 P/E Ratio 0.00
Previous Earnings --
Latest Earnings Mon, Aug 13, 2018
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

2.27 0.04 0.00 0.00 AZRX NASDAQ 0.44 74.62 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AZRX&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AZRX&exchange=NASDAQ&chart=1

Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is a developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.

http://www.brainstorm-cell.com


BCLI $4.11 +0.07 (1.73%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 90 Million
EPS -0.15 P/E Ratio 0.00
Previous Earnings Mon, Jul 23, 2018
Latest Earnings Mon, Oct 29, 2018
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

4.11 0.09 0.00 0.00 BCLI NASDAQ 1.73 18.79 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=BCLI&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=BCLI&exchange=NASDAQ&chart=1

Biocryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, with the aim of blocking key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.

http://www.biocryst.com


BCRX $7.38 -0.52 (-6.58%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 840 Million
EPS -0.25 P/E Ratio 0.00
Previous Earnings Tue, Nov 6, 2018
Latest Earnings Mon, Mar 4, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

7.38 0.84 0.00 0.00 BCRX NASDAQ -6.58 -13.18 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=BCRX&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=BCRX&exchange=NASDAQ&chart=1

BioDelivery Sciences International Inc is a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic pain. The company is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of therapies aimed at addressing important unmet medical needs. Its marketed products and those in development address serious and debilitating conditions such as chronic pain, breakthrough cancer pain, and opioid dependence.

http://www.bdsi.com


BDSI $5.11 -0.19 (-3.58%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 380 Million
EPS -0.08 P/E Ratio 0.00
Previous Earnings Thu, Nov 8, 2018
Latest Earnings Thu, Mar 14, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

5.11 0.38 0.00 0.00 BDSI NASDAQ -3.58 40.00 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=BDSI&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=BDSI&exchange=NASDAQ&chart=1

Biofrontera AG is active in the field of healthcare in the United Kingdom. It manufactures pharmaceutical products, especially medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Its suite of products includes the prescription drugs Ameluz and BF-RhodoLED, for the treatment of actinic keratosis and Belixos, for the regenerative care of reddened and inflamed skin.

http://www.biofrontera.com


BFRA $12.48 +0.08 (0.65%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 280 Million
EPS -0.21 P/E Ratio 0.00
Previous Earnings Fri, Aug 31, 2018
Latest Earnings Fri, Nov 16, 2018
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

12.48 0.28 0.00 0.00 BFRA NASDAQ 0.65 6.58 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=BFRA&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=BFRA&exchange=NASDAQ&chart=1

BeiGene Ltd is a United States based clinical-stage biopharmaceutical company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1.

http://www.beigene.com


BGNE $124.46 -12.16 (-8.90%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 7.52 Billion
EPS -4.55 P/E Ratio 0.00
Previous Earnings Wed, Nov 7, 2018
Latest Earnings Wed, Feb 27, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

124.46 7.52 0.00 0.00 BGNE NASDAQ -8.90 -8.51 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=BGNE&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=BGNE&exchange=NASDAQ&chart=1

Biohaven Pharmaceutical Holding Co Ltd is a clinical-stage biopharmaceutical company. It has a portfolio of late-stage product candidates targeting neurological diseases, including rare disorders. Its product candidates are based on multiple mechanisms-calcitonin gene-related peptide receptor antagonists, glutamate modulators and myeloperoxidase inhibitor. The company's pipeline products include BHV3000-301, BHV3000-302, BHV3000-303 and others.

https://www.biohavenpharma.com


BHVN $50.85 -2.44 (-4.58%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 2.25 Billion
EPS -1.33 P/E Ratio 0.00
Previous Earnings Wed, Nov 14, 2018
Latest Earnings Thu, Feb 28, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

50.85 2.25 0.00 0.00 BHVN NYSE -4.58 38.59 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=BHVN&exchange=NYSE&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=BHVN&exchange=NYSE&chart=1

Bellicum Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. Its research areas are cellular immunotherapies for hematological cancers, solid tumors, and orphan inherited blood diseases. The company's expertise is based on the inclusion of powerful molecular switches planned to eliminate, reduce, or activate therapeutic cells to increase efficacy and safety compared with existing cell therapies. Its pipeline portfolio includes adjunct T-cell therapy (BPX-501) to treat leukemias, lymphomas, and genetic blood diseases; CAR T cells technology (BPX-601) to treat prostate, pancreatic, bladder, esophagus, and gastric cancers; and T cell receptors (BPX-701) to treat blood cancers and solid tumors.

http://www.bellicum.com


BLCM $3.66 -0.03 (-0.81%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 170 Million
EPS -0.63 P/E Ratio 0.00
Previous Earnings Tue, Nov 6, 2018
Latest Earnings Tue, Mar 12, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

3.66 0.17 0.00 0.00 BLCM NASDAQ -0.81 9.91 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=BLCM&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=BLCM&exchange=NASDAQ&chart=1

Bellerophon Therapeutics Inc is a clinical-stage biotherapeutics company. The firm develops innovative products combining novel drugs and devices to treat cardiopulmonary diseases. It develops products under its INOpulse platform, which is an extension of the technology that is used in hospitals to deliver continuous-flow inhaled nitric oxide. The company products are aimed at the treatment of different kinds of pulmonary hypertension.

http://www.bellerophon.com


BLPH $0.72 -0.01 (-1.37%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 50 Million
EPS -0.01 P/E Ratio 0.00
Previous Earnings Wed, Nov 7, 2018
Latest Earnings Thu, Mar 14, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

0.72 0.05 0.00 0.00 BLPH NASDAQ -1.37 -18.18 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=BLPH&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=BLPH&exchange=NASDAQ&chart=1

BioLine Rx Ltd is a clinical-stage biopharmaceutical company, which is engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. It offers products such as BL-1020 which is used to improve cognitive function in schizophrenia patients; BL-1040 for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, for non-surgical removal of skin lesions; BL-1021 for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is used for the treatment of inflammatory bowel disease. Geographically all the operations are functioned from the region of Israel.

http://www.biolinerx.com


BLRX $0.45 -0.01 (-2.17%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 70 Million
EPS -0.06 P/E Ratio 0.00
Previous Earnings Mon, Aug 13, 2018
Latest Earnings Thu, Nov 8, 2018
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

0.45 0.07 0.00 0.00 BLRX NASDAQ -2.17 -10.00 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=BLRX&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=BLRX&exchange=NASDAQ&chart=1

Bluebird Bio is a clinical-stage biotechnology company that develops gene therapies for severe genetic and rare diseases. The company's gene therapy procedures aim to genetically modify a patient's cells to fundamentally correct or address the genetic basis underlying a disease. Bluebird's revenue is derived from collaboration arrangements, research fees, license fees, and grant revenue. The company works with industry peers, strategic partners, and nonprofit organizations for the development and commercialization of its product candidates.

http://www.bluebirdbio.com


BLUE $146.64 -9.54 (-6.11%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 8.57 Billion
EPS -2.73 P/E Ratio 0.00
Previous Earnings Thu, Nov 1, 2018
Latest Earnings Thu, Feb 21, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

146.64 8.57 0.00 0.00 BLUE NASDAQ -6.11 47.38 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=BLUE&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=BLUE&exchange=NASDAQ&chart=1

Audentes Therapeutics Inc is a biotechnology company. It is engaged in developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The company has made some products such as AT132, AT342, AT982 & AT307. Its manufacturing facility is in South San Francisco. The company has established a robust in-house process and analytical development operations for quality purpose.

http://www.audentestx.com


BOLD $36.90 -2.64 (-6.68%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 1.66 Billion
EPS -0.83 P/E Ratio 0.00
Previous Earnings Tue, Nov 6, 2018
Latest Earnings Wed, Feb 27, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

36.90 1.66 0.00 0.00 BOLD NASDAQ -6.68 66.14 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=BOLD&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=BOLD&exchange=NASDAQ&chart=1

Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants.

http://www.blueprintmedicines.com


BPMC $78.58 -5.89 (-6.97%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 3.73 Billion
EPS -1.82 P/E Ratio 0.00
Previous Earnings Tue, Oct 30, 2018
Latest Earnings Tue, Feb 26, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

78.58 3.73 0.00 0.00 BPMC NASDAQ -6.97 53.54 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=BPMC&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=BPMC&exchange=NASDAQ&chart=1

BioSpecifics Technologies Corp is a biopharmaceutical company that specializes in collagenase for multiple indications. Injectable collagenase is marketed in various geographic regions, including the U.S., the EU, and Australia, under the Xiaflex name. The targeted diseases are Dupuytren's contracture and Peyronie's disease. The company is also researching the development of Xiaflex as a solution for new potential indications, such as uterine fibroids, adhesive cabsulitis, cellulite, lateral hip fat, plantar fibromatosis, and human and canine lipomas.

http://www.biospecifics.com


BSTC $65.01 -2.77 (-4.09%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 470 Million
EPS 0.69 P/E Ratio 28.89
Previous Earnings Thu, Aug 9, 2018
Latest Earnings Fri, Nov 9, 2018
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

65.01 0.47 28.89 0.00 BSTC NASDAQ -4.09 8.37 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=BSTC&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=BSTC&exchange=NASDAQ&chart=1

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company which is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501, which is a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. The company's other product candidates are BXCL502 and BXCL702 which is focused on neurodegeneration and hematological malignancies.

http://www.bioxceltherapeutics.com


BTAI $9.18 -0.14 (-1.50%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 140 Million
EPS -0.46 P/E Ratio 0.00
Previous Earnings Fri, Nov 9, 2018
Latest Earnings Thu, Mar 7, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

9.18 0.14 0.00 0.00 BTAI NASDAQ -1.50 163.04 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=BTAI&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=BTAI&exchange=NASDAQ&chart=1

BiondVax Pharmaceuticals Ltd is engaged in the healthcare sector. Its main activity is the commercialization and manufacturing of flu vaccine. Its product is designed to provide multi-season and multi-strain protection against some human influenza virus strains, including both seasonal and pandemic flu strains. The company recently concluded two Phase I/II trials in which the multimeric-001 universal flu vaccine was shown to be safe and immunogenic.

http://www.biondvax.com


BVXV $5.40 -0.19 (-3.40%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 40 Million
EPS -0.40 P/E Ratio 0.00
Previous Earnings Wed, Aug 22, 2018
Latest Earnings Tue, Nov 13, 2018
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

5.40 0.04 0.00 0.00 BVXV NASDAQ -3.40 12.03 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=BVXV&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=BVXV&exchange=NASDAQ&chart=1

BeyondSpring Inc is engaged in clinical stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. The Company has created Plinabulin which is marine derived small-molecule with a number of distinct biological activities that may provide multiple therapeutic opportunities. Plinabulin has increased the survival of neutrophils, a type of white blood cell important in the prevention of bacterial infections. The Company has a scalable business model integrating clinical resources in the United States and China.

http://www.beyondspringpharma.com


BYSI $17.72 +0.21 (1.20%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 410 Million
EPS -0.54 P/E Ratio 0.00
Previous Earnings --
Latest Earnings Tue, Oct 23, 2018
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

17.72 0.41 0.00 0.00 BYSI NASDAQ 1.20 -4.42 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=BYSI&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=BYSI&exchange=NASDAQ&chart=1

Calithera Biosciences Inc is a clinical-stage pharmaceutical company. The business activity of the firm is functioned through the region of US. It focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. Its lead product candidate is CB-839, an inhibitor of glutaminase for the treatment of solid tumors. Its other product candidate, CB-1158, is being developed for hematology and oncology indications.

https://www.calithera.com


CALA $6.41 -0.23 (-3.46%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 250 Million
EPS -0.51 P/E Ratio 0.00
Previous Earnings Wed, Nov 7, 2018
Latest Earnings Thu, Mar 7, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

6.41 0.25 0.00 0.00 CALA NASDAQ -3.46 51.54 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CALA&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CALA&exchange=NASDAQ&chart=1

Capricor Therapeutics Inc is a U.S based clinical-stage biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy, and other medical conditions. The company's development stage drug candidates for cardiovascular diseases include CAP-1002 that is in Phase II clinical trials; and CAP-2003, which is in pre-clinical development for the treatment of certain cardiac and inflammatory conditions.

http://www.capricor.com


CAPR $0.59 0.00 (0.00%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 20 Million
EPS -0.14 P/E Ratio 4.92
Previous Earnings Thu, Aug 9, 2018
Latest Earnings Tue, Nov 13, 2018
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

0.59 0.02 4.92 0.00 CAPR NASDAQ 0.00 18.00 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CAPR&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CAPR&exchange=NASDAQ&chart=1

Cara Therapeutics Inc is an emerging biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.

https://www.caratherapeutics.com


CARA $18.30 -1.34 (-6.82%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 720 Million
EPS -0.52 P/E Ratio 0.00
Previous Earnings Tue, Nov 6, 2018
Latest Earnings Tue, Mar 12, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

18.30 0.72 0.00 0.00 CARA NASDAQ -6.82 25.69 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CARA&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CARA&exchange=NASDAQ&chart=1

CASI Pharmaceuticals Inc is a biopharmaceutical company. It is focused on the acquisition, development, and commercialization of therapeutics addressing cancer and other unmet medical needs with a commercial focus on the China market. The company's technologies include an anti-angiogenesis program that focuses on the development of proprietary products that are intended to inhibit the abnormal growth of new blood vessels associated with cancer and certain causes of blindness. Another EntreMed technology is a blood-cell-permeation device that is designed to enhance the ability of red blood cells to deliver oxygen to organs and tissues.

http://www.casipharmaceuticals.com


CASI $3.11 -0.23 (-6.89%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 310 Million
EPS -0.10 P/E Ratio 0.00
Previous Earnings Tue, Aug 14, 2018
Latest Earnings Wed, Nov 14, 2018
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

3.11 0.31 0.00 0.00 CASI NASDAQ -6.89 -21.27 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CASI&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CASI&exchange=NASDAQ&chart=1

Catabasis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted, a linker-drug discovery platform. The company's primary focus is on treatments for rare diseases. Its product pipeline includes CAT-1004, an oral small molecule for the treatment of Duchenne muscular dystrophy, CAT-2054 for the treatment of hypercholesterolemia and CAT-4001 which is used for the treatment of rare neurodegenerative diseases, such as Friedreich's ataxia and amyotrophic lateral sclerosis.

http://www.catabasis.com


CATB $7.30 -0.16 (-2.14%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 90 Million
EPS -0.62 P/E Ratio 0.00
Previous Earnings Tue, Nov 13, 2018
Latest Earnings Thu, Mar 14, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

7.30 0.09 0.00 0.00 CATB NASDAQ -2.14 64.79 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CATB&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CATB&exchange=NASDAQ&chart=1

CymaBay Therapeutics Inc is a part of the healthcare sector based in the United States. Its main business involves the development of therapeutics such as Arhalofenate, MBX-8025, and MBX-2982. These drugs are intended to treat serious metabolic disorders. Arhalofenate is used to treat gout, MBX-2982 is an oral, G-protein coupled receptor agonist being evaluated as a therapeutic agent for patients with Type 2 diabetes and MBX-8025 is a selective agonist for the peroxisome proliferator-activated receptor delta.

http://www.cymabay.com


CBAY $11.93 -0.99 (-7.66%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 770 Million
EPS -0.32 P/E Ratio 0.00
Previous Earnings Tue, Nov 6, 2018
Latest Earnings Thu, Feb 28, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

11.93 0.77 0.00 0.00 CBAY NASDAQ -7.66 44.43 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CBAY&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CBAY&exchange=NASDAQ&chart=1

Catalyst Biosciences Inc is a clinical-stage biopharmaceutical company. It mainly focuses on developing novel medicines to address serious medical conditions for individuals in need of treatment options. The company emphasizes on product development efforts in the field of hemostasis and to develop valuable therapies for individuals with hemophilia. It is engaged in clinical development of improved, next-generation subcutaneous prophylaxis using enhanced potency Factor VIIa and Factor IX variants.

http://www.catalystbiosciences.com


CBIO $8.51 -0.66 (-7.20%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 110 Million
EPS -0.93 P/E Ratio 0.00
Previous Earnings Thu, Nov 1, 2018
Latest Earnings Thu, Mar 7, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

8.51 0.11 0.00 0.00 CBIO NASDAQ -7.20 3.15 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CBIO&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CBIO&exchange=NASDAQ&chart=1

Cleveland BioLabs Inc is a biopharmaceutical company. The company is developing novel approaches to activate the immune system and address serious medical needs. Its proprietary platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its lead product candidate is entolimod, an immuno-stimulatory agent, which is developed as a radiation countermeasure and an immunotherapy for oncology and other indications. Entolimod is a Toll-like receptor 5 (TLR5) agonist, which is developed as a radiation countermeasure for prevention of death from Acute Radiation Syndrome (ARS), and as an oncology drug.

http://www.cbiolabs.com


CBLI $1.62 -0.05 (-2.99%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 20 Million
EPS -0.04 P/E Ratio 0.00
Previous Earnings --
Latest Earnings --
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

1.62 0.02 0.00 0.00 CBLI NASDAQ -2.99 30.65 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CBLI&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CBLI&exchange=NASDAQ&chart=1

Cambrex Corp is a biotechnology company focused on developing and commercializing new and generic therapeutics. The company primarily supplies its products and services worldwide to innovator and generic pharmaceutical companies. Cambrex's portfolio growth strategy has a particular focus on the later stages of the clinical trial process. It also works to secure long-term supply agreements to produce active pharmaceutical ingredients and intermediates for newly approved drug products. Additionally, Cambrex sometimes works with partners to co-develop portfolios of niche generic drug products in a finished dosage form.

http://www.cambrex.com


CBM $38.19 -1.07 (-2.73%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 1.32 Billion
EPS 0.03 P/E Ratio 10.89
Previous Earnings Thu, Aug 2, 2018
Latest Earnings Thu, Nov 8, 2018
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

38.19 1.32 10.89 0.00 CBM NYSE -2.73 -1.16 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CBM&exchange=NYSE&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CBM&exchange=NYSE&chart=1

Cellular Biomedicine Group Inc is a biotechnology company focused on the development of proprietary cell therapies for the treatment of cancer and degenerative diseases. The company has two major cell platforms: immune cell therapy for treating a broad range of cancers using cancer vaccines, Chimeric Antigen Receptor T-cell technologies, and anti-PD-1 technologies; and human-adipose-derived mesenchymal progenitor cells for treatment of joint and autoimmune diseases. The immuno-oncology and stem cell research team is based in both China and the United States.

http://www.cellbiomedgroup.com


CBMG $16.77 -0.19 (-1.12%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 300 Million
EPS -0.44 P/E Ratio 0.00
Previous Earnings Tue, Nov 6, 2018
Latest Earnings Tue, Feb 19, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

16.77 0.30 0.00 0.00 CBMG NASDAQ -1.12 -10.22 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CBMG&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CBMG&exchange=NASDAQ&chart=1

China Biologic Products Holdings Inc is a biopharmaceutical company principally engaged in the research, development, manufacturing and sales of human plasma-based products in China. The company operates its business through two majority owned subsidiaries, Shandong Taibang and Guizhou Taibang. China Biologic's product pipeline includes a variety of dosages across multiple product categories. Its principal products are human albumin and immunoglobulin for intravenous injection. All of the company's products are prescription medicines administered in the form of injections. China Biologic's sales model focuses on direct sales to hospitals and inoculation centers and is complemented by distributor sales.

http://www.chinabiologic.com


CBPO $87.23 -1.19 (-1.35%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 3.48 Billion
EPS 0.87 P/E Ratio 44.33
Previous Earnings Thu, Nov 1, 2018
Latest Earnings Wed, Mar 6, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

87.23 3.48 44.33 0.00 CBPO NASDAQ -1.35 17.96 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CBPO&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CBPO&exchange=NASDAQ&chart=1

ChemoCentryx Inc is a biopharmaceutical company involved in discovery, development, and commercialization of orally administered drugs to treat rare diseases, inflammatory disorders, autoimmune diseases, and cancer. The company's approach is to target the chemoattractant system, defined as a network of molecules (for example, chemokine ligands, their associated receptors, and chemoattractant receptors) known to cause inflammation. The targeted therapeutic areas are an antineutrophil cytoplasmic antibody, atypical hemolytic uremic syndrome, immunoglobulin A-mediated nephropathy (rare diseases category), pancreatic cancer, chronic kidney disease, psoriasis, rheumatoid arthritis, asthma, Crohn's disease, inflammatory bowel disease, and others.

http://www.chemocentryx.com


CCXI $10.91 +0.41 (3.90%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 570 Million
EPS -0.21 P/E Ratio 0.00
Previous Earnings Thu, Nov 8, 2018
Latest Earnings Mon, Mar 11, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

10.91 0.57 0.00 0.00 CCXI NASDAQ 3.90 -1.45 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CCXI&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CCXI&exchange=NASDAQ&chart=1

Avid Bioservices Inc is a clinical-stage biopharmaceutical company focused on development and current Good Manufacturing Practices (cGMP) of biopharmaceutical products derived from mammalian cell culture. The company provides a comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries.

https://www.avidbio.com


CDMO $4.29 -0.10 (-2.28%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 240 Million
EPS -0.05 P/E Ratio 0.00
Previous Earnings Mon, Dec 10, 2018
Latest Earnings Mon, Mar 11, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

4.29 0.24 0.00 0.00 CDMO NASDAQ -2.28 0.47 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CDMO&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CDMO&exchange=NASDAQ&chart=1

Avid Bioservices Inc is a clinical-stage biopharmaceutical company focused on development and current Good Manufacturing Practices (cGMP) of biopharmaceutical products derived from mammalian cell culture. The company provides a comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries.

https://www.avidbio.com


CDMOP $25.00 -0.65 (-2.53%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 40 Million
EPS 0.00 P/E Ratio 0.00
Previous Earnings Mon, Dec 10, 2018
Latest Earnings Mon, Mar 11, 2019
Dividend 10.50% / $2.63
Ex-Date Fri, Sep 14, 2018
Dividend Pay Date Mon, Oct 1, 2018
Dividend History 19 Payments (Quarterly)

25.00 0.04 0.00 10.50 CDMOP NASDAQ -2.53 -1.26 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CDMOP&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CDMOP&exchange=NASDAQ&chart=1

Cidara Therapeutics Inc functions in the healthcare sector based in the United States. Its business involves the development of novel anti-infectives for the treatment of serious infections, especially caused due to fungus. The company's main drug constitutes echinocandins antifungals in the form of CD101IV and CD101 topical. CD101 IV is a long-acting therapy for the treatment and prevention of serious, invasive fungal infections. CD101 topical, its second product candidate, is being developed for the treatment of vulvovaginal candidiasis. In addition, Cidara has developed a proprietary immunotherapy technology platform, Cloudbreak, which is used to create compounds designed to direct a patient's immune cells to attack and eliminate pathogens that cause infectious diseases.

http://www.cidara.com


CDTX $2.55 -0.06 (-2.30%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 70 Million
EPS -0.41 P/E Ratio 0.00
Previous Earnings Thu, Nov 8, 2018
Latest Earnings Thu, Feb 28, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

2.55 0.07 0.00 0.00 CDTX NASDAQ -2.30 -5.56 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CDTX&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CDTX&exchange=NASDAQ&chart=1

ChromaDex Corp is a science-based integrated nutraceutical company. The products of the company are devoted at improving human immune function. The company produces dietary supplements, skin care, pharmaceutics, and animal health products.

https://www.chromadex.com


CDXC $3.95 0.00 (0.00%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 220 Million
EPS -0.15 P/E Ratio 0.00
Previous Earnings Wed, Nov 7, 2018
Latest Earnings Thu, Mar 7, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

3.95 0.22 0.00 0.00 CDXC NASDAQ 0.00 15.84 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CDXC&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CDXC&exchange=NASDAQ&chart=1

Codexis Inc is involved in the business of providing enzyme optimization services, commercialization of proteins and developing biocatalyst products. The firm's products and services include Screening and Evolution services, Enzymes, Screening Kits. It also develops protein engineering and biocatalyst platforms such as Codeevolver, Ketoreductases, Transminases, Imine reductases etc. The company generates majority of its revenues from research and development activities such as license, technology, access and exclusivity fees, research service fees etc.

https://www.codexis.com


CDXS $19.62 -1.26 (-6.03%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 1.06 Billion
EPS -0.01 P/E Ratio 0.00
Previous Earnings Thu, Nov 8, 2018
Latest Earnings Tue, Feb 26, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

19.62 1.06 0.00 0.00 CDXS NASDAQ -6.03 21.79 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CDXS&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CDXS&exchange=NASDAQ&chart=1

Cerecor Inc is a biopharmaceutical company with commercial operations and research and development capabilities. The Company is building a robust pipeline of innovative therapies in neurology, pediatric healthcare, and orphan rare diseases. The Company is also developing three other neurological clinical and preclinical stage compounds. The Company's pediatric orphan rare disease pipeline is led by CERC-801, CERC-802 and CERC-803. The Company also markets prescription drugs that treat a range of pediatric diseases, disorders and conditions. Cerecor's prescription drugs include Millipred, Ulesfia, Karbinal ER, AcipHex Sprinkle and Cefaclor for Oral Suspension. The Company has marketed medical device, Flexichamber.

https://www.cerecor.com


CERC $5.59 -0.33 (-5.57%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 240 Million
EPS -0.15 P/E Ratio 0.00
Previous Earnings Tue, Nov 13, 2018
Latest Earnings Mon, Mar 18, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

5.59 0.24 0.00 0.00 CERC NASDAQ -5.57 60.17 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CERC&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CERC&exchange=NASDAQ&chart=1

Cerus Corp is a biomedical products company focused in the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East and selected countries in other regions around the world. The firm continues to operate in only one segment: blood safety and generates revenue from the same.

http://www.cerus.com


CERS $6.16 -0.30 (-4.64%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 870 Million
EPS -0.12 P/E Ratio 0.00
Previous Earnings Thu, Nov 1, 2018
Latest Earnings Tue, Feb 26, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

6.16 0.87 0.00 0.00 CERS NASDAQ -4.64 15.36 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CERS&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CERS&exchange=NASDAQ&chart=1

ContraFect Corp is a cinical-stage biotechnology company which focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases including those caused by drug-resistant pathogens, particularly treated in hospital settings. The company has developed advanced lysin product candidate, CF-301 for the treatment of Staph aureus bacteremia, including endocarditis. It also emphasizes on addressing drug-resistant infections using product candidates from its lysin and monoclonal antibody platforms that target conserved regions of either bacteria or viruses. The company operates through a single segment being the Development of therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases.

http://www.contrafect.com


CFRX $0.44 -0.02 (-4.35%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 30 Million
EPS 0.07 P/E Ratio 0.00
Previous Earnings Thu, Aug 9, 2018
Latest Earnings Thu, Nov 8, 2018
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

0.44 0.03 0.00 0.00 CFRX NASDAQ -4.35 -75.28 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CFRX&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CFRX&exchange=NASDAQ&chart=1

Compugen Ltd is a therapeutic discovery company. It is involved in the business of using its predictive discovery infrastructure to identify novel drug targets and develop biologics. The firm's therapeutic pipeline mainly consists of early stage immuno-oncology programs aimed at harnessing the immune system to fight cancer. It focuses on immune checkpoint target candidates which are predicted to serve drug targets for cancer immunotherapies addressing various cancer types and also autoimmune diseases.

http://www.cgen.com


CGEN $3.63 -0.06 (-1.63%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 220 Million
EPS -0.16 P/E Ratio 0.00
Previous Earnings Wed, Aug 1, 2018
Latest Earnings Wed, Nov 7, 2018
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

3.63 0.22 0.00 0.00 CGEN NASDAQ -1.63 54.47 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CGEN&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CGEN&exchange=NASDAQ&chart=1

Chiasma Inc is a biopharmaceutical company which focuses on improving the lives of patients who face challenges associated with existing treatments for their rare and debilitating diseases. Its product candidate includes octreotide capsule which has completed Phase III clinical trial and it is being developed for the potential treatment of acromegaly, a rare, debilitating disease. Chiasma offers its products in the United States.

http://www.chiasmapharma.com


CHMA $5.51 +0.48 (9.54%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 130 Million
EPS -0.33 P/E Ratio 0.00
Previous Earnings Thu, Aug 9, 2018
Latest Earnings Thu, Nov 8, 2018
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

5.51 0.13 0.00 0.00 CHMA NASDAQ 9.54 84.90 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CHMA&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CHMA&exchange=NASDAQ&chart=1

Coherus BioSciences Inc is a United States based biotherapeutics company engaged in developing and commercializing biosimilar therapeutics. The company focuses on process science, analytical characterization, protein production, and clinical-regulatory development. Its pipeline includes Immunology, anti-tumor necrosis factor (Anti-TNF) biosimilar candidates; Ophthalmology biosimilar candidates; and Oncology Biosimilar candidates. Geographically, the group has a business presence in the United States and other countries.

http://www.coherus.com


CHRS $14.32 -1.18 (-7.61%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 990 Million
EPS -0.83 P/E Ratio 0.00
Previous Earnings Wed, Aug 8, 2018
Latest Earnings Thu, Nov 8, 2018
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

14.32 0.99 0.00 0.00 CHRS NASDAQ -7.61 57.02 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CHRS&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CHRS&exchange=NASDAQ&chart=1

Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the US. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR related protein (GITR) and carbonic anhydrase IX (CAIX). It emphasizes on developing novel immuno-oncology and checkpoint inhibitor antibodies as well as oral targeted anti-cancer therapies consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP).

http://www.checkpointtx.com


CKPT $2.90 -0.02 (-0.68%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 100 Million
EPS -0.38 P/E Ratio 0.00
Previous Earnings --
Latest Earnings Fri, Nov 2, 2018
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

2.90 0.10 0.00 0.00 CKPT NASDAQ -0.68 37.44 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CKPT&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CKPT&exchange=NASDAQ&chart=1

Caladrius Biosciences Inc is a therapeutics development biopharmaceutical company. It is engaged in the development of products that have the potential to restore the health of people with chronic illnesses. The company' product candidates include three developmental treatments for cardiovascular diseases; CLBS12 for the treatment of critical limb ischemia (CLI); CLBS14-CMD for the treatment of coronary microvascular dysfunction (CMD); CLBS14-NORDA for no-option refractory disabling angina (NORDA); and one autoimmune product candidate, CLBS03, an ex vivo expanded polyclonal T regulatory cell therapy for the treatment of Type 1 diabetes.

http://www.caladrius.com


CLBS $3.60 -0.02 (-0.55%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 40 Million
EPS -0.36 P/E Ratio 0.00
Previous Earnings Thu, Aug 9, 2018
Latest Earnings Thu, Nov 8, 2018
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

3.60 0.04 0.00 0.00 CLBS NASDAQ -0.55 -11.76 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CLBS&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CLBS&exchange=NASDAQ&chart=1

Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140, and CDX-3379.

http://www.celldex.com


CLDX $4.94 -0.20 (-3.89%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 60 Million
EPS -203.10 P/E Ratio 0.00
Previous Earnings Wed, Aug 8, 2018
Latest Earnings Wed, Nov 7, 2018
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

4.94 0.06 0.00 0.00 CLDX NASDAQ -3.89 31.38 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CLDX&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CLDX&exchange=NASDAQ&chart=1

Collplant Holdings Ltd is a part of the healthcare sector. It is a biotechnology company focused on regenerative medicine. The company operates through its wholly-owned subsidiary which focuses on research, development, manufacture, and marketing of medical products for tissue repair. Its products are based on recombinant human collagen produced from genetically-modified tobacco plants, and the company focuses on orthopedics and advanced wound care.

http://www.collplant.com


CLGN $5.90 +0.15 (2.61%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 20 Million
EPS 1.00 P/E Ratio 0.00
Previous Earnings --
Latest Earnings --
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

5.90 0.02 0.00 0.00 CLGN NASDAQ 2.61 28.54 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CLGN&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CLGN&exchange=NASDAQ&chart=1

Cellectis SA is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the body's immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various university clinical centers. The company's gene-editing technologies allow for the creation of healthy cells derived from healthy donors rather than the patients themselves. The company reports two segments: Therapeutics and Plants. Its Therapeutics segment focuses on novel cancer therapies, while its Plants segment focuses on agricultural biotechnology.

http://www.cellectis.com


CLLS $17.41 -1.26 (-6.75%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 790 Million
EPS -0.55 P/E Ratio 0.00
Previous Earnings Wed, Aug 1, 2018
Latest Earnings Tue, Nov 13, 2018
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

17.41 0.79 0.00 0.00 CLLS NASDAQ -6.75 1.40 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CLLS&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CLLS&exchange=NASDAQ&chart=1

Cellectar Biosciences Inc is a clinical stage biopharmaceutical company. It focusses on development of targeted phospholipid drug conjugates for the treatment and imaging of cancer. The company's pipeline consists of pre-clinical and clinical product candidates including radiotherapeutic and chemotherapeutic phospholipid drug conjugates. Its portfolio of products in development includes CLR 131, CTX Product Portfolio consisting of CTX CLR 1800-P, CTX CLR 1602-PTX and CTX CLR 1700, CLR 125, CLR 124, and CLR 1502.

http://www.cellectar.com


CLRB $2.31 -0.15 (-6.10%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 10 Million
EPS 0.06 P/E Ratio 0.00
Previous Earnings --
Latest Earnings --
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

2.31 0.01 0.00 0.00 CLRB NASDAQ -6.10 46.20 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CLRB&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CLRB&exchange=NASDAQ&chart=1

Clearside Biomedical Inc is a United States based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye. The product candidates of the company focus on disease affecting the retina and aim to restore or improve visual function primarily by reducing the macular edema associated with several diseases affecting vision.

http://www.clearsidebio.com


CLSD $1.43 +0.02 (0.81%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 50 Million
EPS -0.67 P/E Ratio 0.00
Previous Earnings Wed, Aug 8, 2018
Latest Earnings Thu, Nov 8, 2018
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

1.43 0.05 0.00 0.00 CLSD NASDAQ 0.81 24.35 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CLSD&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CLSD&exchange=NASDAQ&chart=1

Celsion Corp is active in the biotechnology market. The company acts as a drug developer with product candidates like ThermoDox, a heat-activated liposomal encapsulation of doxorubicin. It is in Phase III clinical trial for the treatment of primary liver cancer and a Phase II clinical trial for the treatment of recurrent chest wall breast cancer. Its pipeline also includes GEN-1, a deoxyribonucleic acid (DNA) mediated immunotherapy for the localized treatment of ovarian and brain cancers.

http://www.celsion.com


CLSN $2.06 -0.04 (-1.90%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 40 Million
EPS -0.26 P/E Ratio 0.00
Previous Earnings Tue, Aug 14, 2018
Latest Earnings Thu, Nov 15, 2018
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

2.06 0.04 0.00 0.00 CLSN NASDAQ -1.90 23.35 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CLSN&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CLSN&exchange=NASDAQ&chart=1

Clovis Oncology Inc is operative in the healthcare sector based in the United States. As a pharmaceutical manufacturer, it is focused on developing and commercializing anti-cancer agents. Its suite of product candidates includes Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor for the treatment of non-small cell lung cancer. Rucaparib is an oral inhibitor of poly (ADP-ribose) polymerase (PARP) that is in advanced clinical development for the treatment of ovarian cancer. The company's revenue primarily depends on the sale of Rucaparib in the United States market.

https://www.clovisoncology.com


CLVS $24.84 -1.29 (-4.94%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 1.31 Billion
EPS -1.89 P/E Ratio 0.00
Previous Earnings Wed, Aug 1, 2018
Latest Earnings Tue, Oct 30, 2018
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

24.84 1.31 0.00 0.00 CLVS NASDAQ -4.94 28.11 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CLVS&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CLVS&exchange=NASDAQ&chart=1

Chimerix Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of novel, oral antivirals in areas of unmet medical needs. The company's focus is on novel nucleosides with activity against influenza, norovirus, CMV, and BK virus, among others. It derives its revenue from two sources contracts and grants, and collaborations and licensing. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of DNA viruses, including smallpox, adenoviruses, and the human herpesviruses. In addition, the Company has an active discovery program focusing on viral targets for which limited or no therapies are currently available.

http://www.chimerix.com


CMRX $2.00 0.00 (0.00%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 100 Million
EPS -0.29 P/E Ratio 0.00
Previous Earnings Wed, Aug 8, 2018
Latest Earnings Thu, Nov 8, 2018
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

2.00 0.10 0.00 0.00 CMRX NASDAQ 0.00 -25.37 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CMRX&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CMRX&exchange=NASDAQ&chart=1

Clementia Pharmaceuticals Inc is a clinical stage biopharmaceutical company. It is developing disease-modifying treatments for patients suffering from debilitating bone and other diseases with high unmet medical need. The company's lead product candidate, palovarotene, is an oral small molecule that has shown potent activity in preventing abnormal new bone formation as well as fibrosis in a variety of tissues. Clementia is developing palovarotene for the treatment of Fibrodysplasia Ossificans Progressiva (FOP) and Multiple Osteochondroma (MO). It believes that if approved in FOP or MO, palovarotene could become the standard of care in either or both of these indications.

http://www.clementiapharma.com


CMTA $26.00 +0.09 (0.35%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 990 Million
EPS -0.46 P/E Ratio 9.77
Previous Earnings Thu, Aug 9, 2018
Latest Earnings Wed, Nov 7, 2018
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

26.00 0.99 9.77 0.00 CMTA NASDAQ 0.35 105.53 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CMTA&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CMTA&exchange=NASDAQ&chart=1

Conatus Pharmaceuticals Inc is a biotechnology company. It focuses on the development and commercialization of novel medicines to treat liver disease. The company is developing emricasan, an orally active pan-caspase protease inhibitor, for the treatment of patients with the chronic liver disease.

https://www.conatuspharma.com


CNAT $1.28 -1.63 (-56.01%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 40 Million
EPS -0.12 P/E Ratio 0.00
Previous Earnings Wed, Aug 1, 2018
Latest Earnings Thu, Nov 1, 2018
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

1.28 0.04 0.00 0.00 CNAT NASDAQ -56.01 -29.28 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CNAT&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CNAT&exchange=NASDAQ&chart=1

Concert Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company aims to discover and develop small-molecule drugs by incorporating new elements into known molecules or by leveraging the current approved drugs to be used for new treatments. The pipeline consists of small molecules designed for oral administration to cure cystic fibrosis, inflammation, narcolepsy, residual schizophrenia, major depressive disorder, and Alzheimer's agitation.

https://www.concertpharma.com


CNCE $15.51 -2.03 (-11.57%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 360 Million
EPS -0.89 P/E Ratio 0.00
Previous Earnings Thu, Aug 2, 2018
Latest Earnings Thu, Nov 1, 2018
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

15.51 0.36 0.00 0.00 CNCE NASDAQ -11.57 14.30 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CNCE&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CNCE&exchange=NASDAQ&chart=1

Constellation Pharmaceuticals Inc is a United States based clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead products include CPI-0610, which is a small molecule designed to promote anti-tumor activity by specifically inhibiting the function of BET proteins, which normally enhance target gene expression, and CPI-1205 which is a small molecule designed to promote anti-tumor activity by specifically inhibiting EZH2, an enzyme that suppresses target gene expression. It operates in the segment of the development of novel therapeutics in the field of epigenetics.

http://www.constellationpharma.com


CNST $11.25 -0.24 (-2.09%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 290 Million
EPS 0.45 P/E Ratio 0.00
Previous Earnings Tue, Aug 14, 2018
Latest Earnings Thu, Nov 8, 2018
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

11.25 0.29 0.00 0.00 CNST NASDAQ -2.09 156.85 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CNST&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CNST&exchange=NASDAQ&chart=1

Global Cord Blood Corp provides cord blood banking services. The company provides cord blood processing and storage services for expectant parents interested in capturing the evolving medical treatments & technologies such as cord blood transplants.

http://www.globalcordbloodcorp.com


CO $7.06 -0.09 (-1.26%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 860 Million
EPS 0.51 P/E Ratio 26.13
Previous Earnings Thu, Aug 23, 2018
Latest Earnings Tue, Nov 27, 2018
Dividend 1.13% / $0.08
Ex-Date --
Dividend Pay Date --
Dividend History 9 Payments (Quarterly)

7.06 0.86 26.13 1.13 CO NYSE -1.26 13.87 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CO&exchange=NYSE&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CO&exchange=NYSE&chart=1

Cocrystal Pharma Inc is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. The company employs structure-based technologies and Nobel Prize winning expertise to create first-and best-in-class antiviral drugs. The Company is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). CC-31244 is currently being evaluated in a Phase 2a study for the treatment of hepatitis C as part of a cocktail for ultra-short therapy of 4 to 6 weeks. The company recently entered into an exclusive license and collaboration agreement with Merck & Co., Inc.

http://www.cocrystalpharma.com


COCP $2.80 +0.01 (0.36%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 80 Million
EPS -0.06 P/E Ratio 69.95
Previous Earnings Thu, Aug 9, 2018
Latest Earnings Mon, Nov 12, 2018
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

2.80 0.08 69.95 0.00 COCP NASDAQ 0.36 -25.93 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=COCP&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=COCP&exchange=NASDAQ&chart=1

Corium International Inc is a commercial-stage biopharmaceutical company which is focused on the development, manufacture, and commercialization of specialty pharmaceutical products. The company has multiple proprietary programs in preclinical and clinical development focusing primarily on the treatment of neurological disorders. It has few proprietary transdermal platforms such as Corplex for small molecules and MicroCor which is a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides, and proteins. The company's products include Clonidine TDS, Fentanyl TDS, and Crest Whitestrips.

http://www.coriumgroup.com


CORI $12.68 +0.03 (0.24%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 460 Million
EPS -0.34 P/E Ratio 0.00
Previous Earnings Mon, May 14, 2018
Latest Earnings Thu, Aug 9, 2018
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

12.68 0.46 0.00 0.00 CORI NASDAQ 0.24 23.95 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CORI&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CORI&exchange=NASDAQ&chart=1

Corcept Therapeutics Inc is engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders by modulating the effects of cortisol.

http://www.corcept.com


CORT $11.17 -0.66 (-5.58%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 1.28 Billion
EPS 0.19 P/E Ratio 18.62
Previous Earnings Thu, Aug 9, 2018
Latest Earnings Thu, Nov 1, 2018
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

11.17 1.28 18.62 0.00 CORT NASDAQ -5.58 -19.18 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CORT&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CORT&exchange=NASDAQ&chart=1

Corbus Pharmaceuticals Holdings Inc is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.

http://www.corbuspharma.com


CRBP $7.05 -0.63 (-8.20%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 490 Million
EPS -0.31 P/E Ratio 0.00
Previous Earnings Thu, Nov 8, 2018
Latest Earnings Tue, Mar 12, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

7.05 0.49 0.00 0.00 CRBP NASDAQ -8.20 7.63 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CRBP&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CRBP&exchange=NASDAQ&chart=1

Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include CUDC-907, CA-170, CA-4948, CA-327, and Erivedge.

http://www.curis.com


CRIS $1.43 +0.06 (4.38%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 50 Million
EPS -0.22 P/E Ratio 0.00
Previous Earnings Thu, Aug 2, 2018
Latest Earnings Thu, Nov 1, 2018
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

1.43 0.05 0.00 0.00 CRIS NASDAQ 4.38 74.39 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CRIS&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CRIS&exchange=NASDAQ&chart=1

Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.

https://www.crinetics.com


CRNX $23.60 -1.20 (-4.84%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 580 Million
EPS 0.06 P/E Ratio 0.00
Previous Earnings Thu, Aug 30, 2018
Latest Earnings Tue, Nov 13, 2018
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

23.60 0.58 0.00 0.00 CRNX NASDAQ -4.84 -19.48 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CRNX&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CRNX&exchange=NASDAQ&chart=1

CRISPR Therapeutics AG is a gene-editing company. It is engaged in the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 is a technology that allows for precise, directed changes to genomic DNA. The company advanced programs target beta-thalassemia and sickle cell disease, two hemoglobinopathies that have a high unmet medical need.

http://www.crisprtx.com


CRSP $35.59 -2.27 (-6.00%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 1.86 Billion
EPS -0.93 P/E Ratio 0.00
Previous Earnings Wed, Nov 7, 2018
Latest Earnings Mon, Feb 25, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

35.59 1.86 0.00 0.00 CRSP NASDAQ -6.00 19.15 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CRSP&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CRSP&exchange=NASDAQ&chart=1

CORVUS PHARMACEUTICALS INC
CRVS $4.01 -0.39 (-8.86%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 190 Million
EPS -0.36 P/E Ratio 0.00
Previous Earnings Thu, Nov 1, 2018
Latest Earnings Thu, Mar 7, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

4.01 0.19 0.00 0.00 CRVS NASDAQ -8.86 -6.09 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CRVS&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CRVS&exchange=NASDAQ&chart=1

Champions Oncology Inc is a US-based company which is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segments namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). The POS business assists physicians in developing personalized treatment options for their cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies.

http://www.championsoncology.com


CSBR $10.09 -0.30 (-2.89%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 120 Million
EPS -0.03 P/E Ratio 0.00
Previous Earnings Mon, Jul 30, 2018
Latest Earnings Mon, Mar 18, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

10.09 0.12 0.00 0.00 CSBR NASDAQ -2.89 94.28 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CSBR&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CSBR&exchange=NASDAQ&chart=1

CTI BioPharma Corp is a biopharmaceutical company focused on the acquisition, development, and commercialization of less toxic and more effective cancer therapies. The company's therapeutic area is blood-related cancers. Its products under pipeline include PIXUVRI, and Pacritinib. PIXUVRI is a novel aza-anthracenedione with unique structural and physiochemical properties. Pacritinib is an investigational oral kinase inhibitor for the treatment of adult patients with myelofibrosis.

http://www.ctibiopharma.com


CTIC $0.96 -0.03 (-3.03%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 60 Million
EPS 0.03 P/E Ratio 0.00
Previous Earnings Thu, Nov 1, 2018
Latest Earnings Wed, Mar 13, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

0.96 0.06 0.00 0.00 CTIC NASDAQ -3.03 3.23 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CTIC&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CTIC&exchange=NASDAQ&chart=1

CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company which is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platform. The company probody technology platform to create proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of unique conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. The company focuses on developing Probody therapeutics which addresses clinically-validated cancer targets in immuno-oncology that are difficult to drug and lead to concerns about damage to healthy tissues or toxicities.

https://www.cytomx.com


CTMX $10.41 -0.73 (-6.55%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 490 Million
EPS -0.74 P/E Ratio 0.00
Previous Earnings Tue, Nov 6, 2018
Latest Earnings Wed, Feb 27, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

10.41 0.49 0.00 0.00 CTMX NASDAQ -6.55 -33.35 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CTMX&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CTMX&exchange=NASDAQ&chart=1

ContraVir Pharmaceuticals Inc is a United States-based biopharmaceutical company engaged in the development of targeted pharmaceutical therapies for liver disease. The company focuses on developing two novel oral compounds to treat HBV infection. CRV431 is a cyclophilin inhibitor that targets specific isomerases that play an important role in protein folding in health and in disease. TXL is a nucleotide pro-drug of tenofovir that inhibits hepatitis B viral replication and targets the liver, the reservoir for the hepatitis B virus.

https://www.contravir.com


CTRV $0.24 -0.02 (-7.69%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 10 Million
EPS -0.05 P/E Ratio 0.00
Previous Earnings --
Latest Earnings --
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

0.24 0.01 0.00 0.00 CTRV NASDAQ -7.69 -17.24 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CTRV&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CTRV&exchange=NASDAQ&chart=1

Citius Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in the development and commercialization of anti-infective products, adjunctive cancer care, and unique prescription products. Citius is currently advancing two proprietary product candidates, Mino-Lok product and a Hydrocortisone-Lidocaine formulation. Mino-Lok product is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections. The company's Hydrocortisone-Lidocaine provides anti-inflammatory and anesthetic relief to patients suffering from Grade I and II hemorrhoids. The company is primarily operating within the critical care and cancer care market segments.

http://www.citiuspharma.com


CTXR $1.28 -0.14 (-9.86%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 30 Million
EPS -0.22 P/E Ratio 0.00
Previous Earnings --
Latest Earnings --
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

1.28 0.03 0.00 0.00 CTXR NASDAQ -9.86 18.52 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CTXR&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CTXR&exchange=NASDAQ&chart=1

Cue Biopharma Inc is a biopharmaceutical company. It is developing a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its lead drug candidate comprises CUE-101, a variant form of the cytokine Interleukin-2 and a T cell antigen to target and activate T cells specific to HPV-related cancers.

https://www.cuebiopharma.com


CUE $7.95 -0.70 (-8.09%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 160 Million
EPS -0.58 P/E Ratio 0.00
Previous Earnings Mon, Aug 13, 2018
Latest Earnings Tue, Nov 13, 2018
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

7.95 0.16 0.00 0.00 CUE NASDAQ -8.09 54.07 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CUE&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CUE&exchange=NASDAQ&chart=1

Neuralstem Inc is a clinical-stage biopharmaceutical company. The company is engaged in research, development, and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. Its technology base has produced three primary assets: NSI-189 small molecule program, NSI-566 stem cell therapy program and novel and proprietary new chemical entity screening platform.

http://www.neuralstem.com


CUR $0.60 -0.05 (-7.69%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 10 Million
EPS -0.12 P/E Ratio 0.00
Previous Earnings --
Latest Earnings --
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

0.60 0.01 0.00 0.00 CUR NASDAQ -7.69 81.82 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CUR&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CUR&exchange=NASDAQ&chart=1

CohBar Inc is a biotechnology company. It is engaged in the research and development of mitochondria based therapeutics (MBTs) to treat various diseases associated with aging and metabolic dysfunction. The product portfolio of the company includes drug such as CB4209 and CB4211, SHLP-6, SHLP-2 and new MBTs, these address a broad range of age-related diseases, including obesity, fatty liver disease, Type-2 diabetes, cancer, cardiovascular and neurodegenerative diseases. Geographically all the operation of the group is functioned through the region of United States.

https://www.cohbar.com


CWBR $3.09 -0.11 (-3.44%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 130 Million
EPS -0.10 P/E Ratio 0.00
Previous Earnings Wed, Nov 14, 2018
Latest Earnings Mon, Mar 18, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

3.09 0.13 0.00 0.00 CWBR NASDAQ -3.44 -9.65 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CWBR&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CWBR&exchange=NASDAQ&chart=1

Celyad SA is a biopharmaceutical company, specialized in cell therapy. It develops technologies and treatments to treat severe diseases with poor prognosis. The company focuses on Immuno oncology, Cardiology, and Medical devices. Its main product candidates include CAR-T NKR-2, C-Cure. The firm has CYAD-01, CYAD-02, CYAD-03 programs in pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CATH and C-CATHez and CARDIO 3 BIOSCIENCES. The firm has Cardiology and Corporate operating segments. It derives majority of its revenues from Cardiology segment.

http://www.celyad.com


CYAD $20.52 -1.35 (-6.17%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 250 Million
EPS -6.13 P/E Ratio 0.00
Previous Earnings Thu, Aug 23, 2018
Latest Earnings Wed, Nov 21, 2018
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

20.52 0.25 0.00 0.00 CYAD NASDAQ -6.17 3.85 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CYAD&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CYAD&exchange=NASDAQ&chart=1

Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company which develops targeted medicines for cancer and other proliferative diseases. It develops several families of anticancer drugs that act on the cell cycle, including nucleoside analogs, CDK (cyclin dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include CYC065 CDK inhibitor, Sapacitabine and seliciclib, CYC682, CYC140 PLK inhibitor, and CYC202. The company earns the majority of its revenue from the United Kingdom.

http://www.cyclacel.com


CYCC $0.95 -0.02 (-2.06%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 10 Million
EPS -0.18 P/E Ratio 0.00
Previous Earnings --
Latest Earnings --
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

0.95 0.01 0.00 0.00 CYCC NASDAQ -2.06 37.68 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CYCC&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CYCC&exchange=NASDAQ&chart=1

Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatment for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The treatment is based on small molecules specifically engineered to increase muscle function and contractility.

http://www.cytokinetics.com


CYTK $8.75 -0.09 (-1.02%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 480 Million
EPS -0.48 P/E Ratio 0.00
Previous Earnings Thu, Nov 1, 2018
Latest Earnings Thu, Feb 21, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

8.75 0.48 0.00 0.00 CYTK NASDAQ -1.02 28.30 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CYTK&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CYTK&exchange=NASDAQ&chart=1

CytRx Corp operates in the healthcare sector of the United States. It is focused on the development of aldoxorubicin, which is meant to cure soft tissue sarcoma, a kind of tumor. It is also engaged in the pre-clinical development for DK049, an anti-cancer drug conjugate that utilizes its Linker Activated Drug Release (LADR) technology.

http://www.cytrx.com


CYTR $0.61 +0.01 (1.67%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 20 Million
EPS -0.10 P/E Ratio 0.00
Previous Earnings Mon, Aug 6, 2018
Latest Earnings Fri, Nov 2, 2018
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

0.61 0.02 0.00 0.00 CYTR NASDAQ 1.67 17.31 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CYTR&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CYTR&exchange=NASDAQ&chart=1

Cytori Therapeutics Inc is a specialty therapeutics company. It is committed to providing meaningful and quality therapeutic options with a broad utility that benefit patients and healthcare providers around the world. To meet this objective, the company has two therapeutic development platforms, Cytori Cell Therapy (CCT) and Cytori Nanomedicine. The company's CCT, platform, is based on the scientific discovery that the human adipose or fat tissue compartment is a source of a unique mixed population of stem, progenitor and regenerative cells. Its Cytori Nanomedicine Platform features a versatile and novel protein-stabilized liposomal nanoparticle technology for drug encapsulation that provides the foundation to bring two promising drugs into early/late stage clinical trials.

http://www.cytori.com


CYTX $0.24 -0.02 (-7.69%)
Sector Health Care
Industry Biotech & Pharma
Market Cap --
EPS -0.55 P/E Ratio 0.00
Previous Earnings --
Latest Earnings --
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

0.24 0.00 0.00 0.00 CYTX NASDAQ -7.69 -25.00 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CYTX&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CYTX&exchange=NASDAQ&chart=1

Dare Bioscience Inc is a clinical-stage biopharmaceutical company focused on women's reproductive health. The products of the company are related to fertility, vaginal health, and contraception. Ovaprene is a product designed by the company to provide multiple weeks of contraceptive protection without the use of hormones.

https://www.darebioscience.com


DARE $1.68 -0.25 (-12.95%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 20 Million
EPS -0.23 P/E Ratio 0.00
Previous Earnings --
Latest Earnings --
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

1.68 0.02 0.00 0.00 DARE NASDAQ -12.95 127.03 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=DARE&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=DARE&exchange=NASDAQ&chart=1

DBV Technologies SA is a biotechnology company that provides therapy for food and pediatric allergy patients. The company focuses on discovering, developing, manufacturing, and commercializing treatments for severe allergies in the United States and other global markets. DBV's method of delivering biologically active compounds to the immune system is through self-administered and noninvasive products. The company also explores potential applications of its platform in vaccines and other immune diseases.

http://www.dbv-technologies.com


DBVT $7.64 -0.53 (-6.49%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 500 Million
EPS 0.00 P/E Ratio 0.00
Previous Earnings Fri, Sep 7, 2018
Latest Earnings Tue, Mar 5, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

7.64 0.50 0.00 0.00 DBVT NASDAQ -6.49 9.30 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=DBVT&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=DBVT&exchange=NASDAQ&chart=1

Deciphera Pharmaceuticals Inc is a biotechnology company, develops and manufactures kinase-inhibiting drugs for the treatment of cancers and immunological diseases. It holds a diverse pipeline of drug candidates that includes three clinical-stage and two research-stage programs. Its lead drug candidate DCC-2618 is designed to inhibit the full spectrum of mutant or amplified KIT and Pdgfra kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. In addition it is also developing two other clinical-stage drug candidates, DCC-3014 and Rebastinib. Geographically all the operations are functioned through the region of US.

https://www.deciphera.com


DCPH $23.94 -0.52 (-2.13%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 920 Million
EPS -0.87 P/E Ratio 0.00
Previous Earnings Thu, Nov 8, 2018
Latest Earnings Thu, Mar 14, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

23.94 0.92 0.00 0.00 DCPH NASDAQ -2.13 6.49 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=DCPH&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=DCPH&exchange=NASDAQ&chart=1

Dermira Inc is a biopharmaceutical company focuses on the development and commercialization of medical dermatology products to dermatologists and their patients primarily in the United States.The company's late-stage product candidates include Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor to treat various inflammatory diseases, as well as to treat patients with moderate-to-severe chronic plaque psoriasis; Glycopyrronium tosylate, a small-molecule anticholinergic product that is in Phase III clinical trial for the treatment of primary axillary hyperhidrosis or excessive underarm sweating; and Olumacostat glasaretil, a small-molecule sebum inhibitor, which is in Phase III clinical trial to treat acne vulgaris or acne.

http://www.dermira.com


DERM $12.99 -0.63 (-4.63%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 550 Million
EPS -1.70 P/E Ratio 0.00
Previous Earnings Wed, Nov 7, 2018
Latest Earnings Tue, Feb 26, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

12.99 0.55 0.00 0.00 DERM NASDAQ -4.63 76.26 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=DERM&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=DERM&exchange=NASDAQ&chart=1

Diffusion Pharmaceuticals Inc is a clinical stage biotechnology company. It is focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard-of-care treatments, including radiation therapy and chemotherapy. Its lead product candidate is trans sodium crocetinate (TSC), which is used for the treatment of glioblastoma multiforme (GBM); Phase II pancreatic cancer; and metastatic brain cancer. Geographically business activity of the firm is functioned through the region of US.

http://www.diffusionpharma.com


DFFN $4.70 -0.18 (-3.69%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 20 Million
EPS -1.95 P/E Ratio 0.00
Previous Earnings --
Latest Earnings --
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

4.70 0.02 0.00 0.00 DFFN NASDAQ -3.69 123.81 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=DFFN&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=DFFN&exchange=NASDAQ&chart=1

DelMar Pharmaceuticals Inc is a clinical and commercial stage drug development company, which focuses on the research and development of drugs for the treatment of cancer. The company's principal product candidate includes VAL-083, a small-molecule chemotherapeutic agent, which is in clinical trials stage for the treatment of refractory glioblastoma multiforme, a form of brain cancer. DelMar also has a strategic collaboration with Guangxi Wuzhou Pharmaceutical for the development of VAL-083 used in treating chronic myelogenous leukemia and lung cancer. All the business activity of the firm is functioned through the region of Canada.

http://www.delmarpharma.com


DMPI $0.50 -0.01 (-1.96%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 10 Million
EPS -0.08 P/E Ratio 0.00
Previous Earnings --
Latest Earnings --
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

0.50 0.01 0.00 0.00 DMPI NASDAQ -1.96 42.86 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=DMPI&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=DMPI&exchange=NASDAQ&chart=1

DENALI THERAPEUTICS INC
DNLI $19.45 -0.87 (-4.28%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 1.76 Billion
EPS 0.82 P/E Ratio 0.00
Previous Earnings Thu, Aug 9, 2018
Latest Earnings Tue, Mar 12, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

19.45 1.76 0.00 0.00 DNLI NASDAQ -4.28 0.62 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=DNLI&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=DNLI&exchange=NASDAQ&chart=1

Dova Pharmaceuticals Inc is the United States based clinical-stage pharmaceutical company engaged in developing treatments for patients suffering from orphan diseases. It is focused on acquiring, developing and commercializing drug candidates for diseases that are treated by specialist physicians, with an initial focus on addressing thrombocytopenia, a disorder characterized by a low blood platelet count. The company's drug candidate, avatrombopag, is an orally administered thrombopoietin receptor agonist, or TPO-RA, that it is developing for the treatment of thrombocytopenia. The company's drug candidate, avatrombopag, is designed to mimic the effects of thrombopoietin, in vitro and in vivo. Thrombopoietin is a hormone produced in the liver and kidney that binds to its receptor.

http://www.dova.com


DOVA $8.80 -0.57 (-6.08%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 250 Million
EPS -0.69 P/E Ratio 0.00
Previous Earnings Thu, Aug 9, 2018
Latest Earnings Thu, Nov 8, 2018
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

8.80 0.25 0.00 0.00 DOVA NASDAQ -6.08 0.69 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=DOVA&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=DOVA&exchange=NASDAQ&chart=1

Dicerna Pharmaceuticals Inc is a biotechnology company involved in the discovery and development of innovative treatments for rare inherited diseases affecting the liver, along with cancers, and other therapeutic areas to address liver problems. The company is using ribonucleic acid interference (RNA) technology platform to develop its products. The product candidates are DCR-PHXC (for primary hyperoxaluria), DCR-undisclosed (for orphan genetic disease), DCR-PCSK9 (for cardiovascular disease), and DCR-HBV (for hepatitis B virus) among others.

https://www.dicerna.com


DRNA $13.29 -0.75 (-5.34%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 910 Million
EPS -0.28 P/E Ratio 0.00
Previous Earnings Wed, Aug 8, 2018
Latest Earnings Mon, Nov 5, 2018
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

13.29 0.91 0.00 0